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Drug substances are most frequently administered as solid dosage formulations, mainly by 
the oral route. The drug substance’s physicochemical characteristics, as well the excipients 
added to the formulations, all contribute to ensuring the desired therapeutic activity. Some of 
the solid dosage forms are tablets, capsules, pills, lozenges, cachets and powders. Tablets and 
capsules are the most frequently used solid dosage forms, have been in existence since the 
nineteenth century, and are unit dosage forms, comprising a mixture of ingredients presented 
in a single rigid entity, usually containing an accurate dose of a drug. 
1. TABLETS: [1]  
 A tablet is a pharmaceutical dosage form. It comprises a mixture of active substances 
and excipients, usually in powder form, pressed or compacted from a powder into a solid 
dose.  A polymer coating is often applied to make the tablet smoother and easier to swallow, 
to control the release rate of the active ingredient, to make it more resistant to the 
environment (extending its shelf life), or to enhance the tablet's appearance. 
 Advantages: 
                     a. Easy to handle 
b. Variety of manufacturing methods 
                     c. Can be mass produced at low cost 
                     d. Consistent quality and dosing precision 
                     e. Can be self - administered 
                 f. Enhanced mechanical, chemical, and microbiological stability compared to     
liquid dosage forms 
                 g. Tamperproof 
                  h. Lend themselves to adaptation for other profiles. 
    
 Disadvantages: 
                      a.   Difficulty of swallowing by children and ill patients. 
                 b. Drugs that are liquid at room temperature cannot be formulated in tablet 
dosage form.  
                  c.   Drugs with poor wetting and slow dissolution properties are difficult to    
convert into tablets. 
                  d.    Bitter tasted drugs need special treatment like coating. 
                  e. Drugs with high doses are difficult to formulate. 
 
1.2 GENERAL PROPERTIES OF TABLETS: 
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   1.  A tablet should have elegant product identity while free of defects like chips, Cracks,    
discoloration and contamination.  
   2.  Should have sufficient strength to withstand mechanical shock during its production 
packaging, shipping and dispensing.   
   3.  Should have the chemical and physical stability to maintain its physical attributes   
over time 
   4.  The tablet must be able to release the medicinal agents in a predictable and 
reproducible manner.  
   5.    Tablet must have a chemical stability to with stand   in all the temperatures. 
 
1.3 MODIFIED RELEASE DOSAGE FORM:[2] 
              Dosage forms can be designed to modify the release of the drug over a given time or 
after the dosage form reaches the required location. Drug release only occurs some time after 
the administration or for a prolonged period of time or to a specific target in the body. 
Modifications in drug release are often desirable to increase the stability, safety and efficacy 
of the drug, to improve the therapeutic outcome of the drug treatment and/or to increase 
patient compliance and convenience of administration. 
1.4 TYPES OF DOSAGE FORMS:   
1.4.1Oral Dosage Forms 
        Modified release dosage forms  
        Sustained release e.g.  Controlled release  
                                             Prolonged release  
        Delayed release e.g. Enteric-coated tablets                                                                                                 
1.4.2 Intramuscular Dosage Forms 
       Depot injections  
       Water-immiscible injections e.g. oils  
 1.4.3 Subcutaneous Dosage Forms 
       Implants   
 1.4.4 Transdermal Delivery Systems 
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      Patches, creams, etc.  
 1.4.5 Targeted Delivery System 
                  Sustained release drug delivery system is capable of achieving the benefit over the 
conventional dosage forms. 
  1.3 ADVANTAGES  
  1.3.1   Therapeutic advantages                         
                    Reduction in drug plasma level fluctuation; maintenance of a steady plasma level 
of the drug over a prolonged time period, ideally simulating an intravenous infusion of a 
drug.  
  1.3.2    Reduction in adverse side effects                                        
                     Drug plasma levels are maintained within a narrow window with no sharp peaks 
and with AUC of plasma concentration versus time curve comparable with total AUC from 
multiple dosing with immediate release dosage forms 
  1.3.3    Patient comfort and compliance                                 
                   Oral drug delivery is the most common and convenient for patients, and a 
reduction in dosing frequency enhances compliance.  
  1.3.4    Reduction in healthcare cost                                        
The total cost of therapy of the controlled release product could be comparable or 
lower than the immediate release product. with reduction in side effects, the overall expense 
in disease management also reduced.  
 1.3.5 Avoid nights time dosing 
It is also good for patients to avoid the dosing at night time.  
 1.4. DRAWBACKS ASSOCIATED WITH CONVENTIONAL DOSAGE FORMS: 
1. Poor patient compliance, increased chances of missing the dose of a drug with short 
half-life for which frequent administration is necessary.  
2. The unavoidable fluctuations of drug concentration may lead to under medication 
or over medication.  
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3. A typical peak-valley plasma concentration-time profile is obtained which    makes 
attainment of steady-state condition difficult.  
4. The fluctuations in drug levels may lead to precipitation of adverse effects 
especially of a drug with small Therapeutic Index (TI) whenever over medication occur.  
1.5 SUSTAINED DRUG DELIVERY SYSTEM:[3] 
                                Sustained release dosage forms are designed to release a drug at a 
predetermined rate in order to maintain a constant drug concentration for a specific 
period of time with minimum side effects. 
1.5.1 Drug Properties Relevant to Sustained – release Formulation: 
      The sustained-release products are often designed with an initial dose intended to 
establish rapidly therapeutic drug blood levels and additional drug intended to maintain those 
levels for prolonged periods.  Those products providing only the slow-release component and 
lacking the immediate-release component have sometimes been termed prolonged release.   
       The term “sustained release” is used to describe a pharmaceutical dosage form 
formulated to retard the release of a therapeutic agent such that its appearance in the systemic 
circulation is delayed and/or prolonged and its plasma profile is sustained in duration. 
PROPERTIES AFFECTING PERFORMANCE OF SUSTAIN RELEASE 
FORMULATIONS: 
A number of variables, such as drug properties including stability, solubility, partioning 
characteristics, protein binding, routes of drug delivery and the patient must establish the 
criteria for designing controlled/sustained release products. Physiochemical and biological 
factors since the biological properties of a drug are a function of its physiochemical 
properties while biological properties result from typical pharmacokinetic studies on the 
absorption, distribution, metabolism and excretion (ADME) characteristics of a drug as well 
as those resulting from pharmacological studies 
A .Physicochemical Properties: 
1. Aqueous solubility and PKa: 
 The aqueous solubility of a drug influences its dissolution rate, which in turn 
establishes its concentration in solution and hence the driving force for diffusion across 
membranes.  Dissolution rate is related to aqueous solubility as shown by the Noyes – 
Whitney equation which, under sink condition, is  
  Dc/dt = KDACs 
  dc/dt= dissolution rate 
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  KD = dissolution rate constant 
  A = total surface area of the drug particles and 
  Cs = aqueous saturation solubility of the drug 
 The dissolution rate is constant only if surface area, A, remains constant, but the 
important point to note is that initial rate is proportional directly to aqueous solubility Cs.  
Therefore, the aqueous solubility of a drug can be used as a first approximation of its 
dissolution rate.  Low solubility limits the dissolution rate and hence the absorption of many 
drugs. 
  In general, high aqueous solubility of a drug is undesirable for formulation into a 
sustained release product.  A drug with very low solubility and a slow dissolution rate will 
exhibit dissolution-limited absorption and yield an inherently sustained blood level.  In most 
instances, formulation of such a drug into a sustained released system is redundant. 
 
2. Partition coefficient: 
Partition coefficient is the measure of a drug‘s lipophilicity and an indication of its ability to 
cross call membrane 
 Between the time that a drug is administered and the time it is eliminated from the 
body, it must diffuse through a variety of biological membranes which act primarily as  
lipid-like barriers.  
 A major criterion in evaluation of the ability of a drug to penetrate these lipid 
membranes is its apparent oil/water partition coefficient, defined as  
     K = Co/Cw 
  
 Co = total concentration of all forms of the drug. E.g. ionized and unionized, in some 
organic phased at equilibrium, and  
 Cw = total concentration of all forms in an aqueous phase at equilibrium 
                                                                                         INTRODUCTON 
 
Page 6 
 
 
Figure: 1. Typical relationship between drug activity and partition coefficient K, 
Generally known as the Hansch correlation. 
            Drugs with a partition coefficient that either is extremely higher of lower that the 
optimum are, in general, poorer candidates for formulation into sustained release dosage 
forms. 
3. Drug Stability: 
                        The drug in the solid state undergoes degradation at a much slower rate than a 
drug in suspension or solution; it would be seen possible to improve significantly the 
bioavailability of a drug, which is unstable in the GI tract by placing it in a slowly available 
sustained release form.  For those drugs that are unstable in the stomach, the appropriate 
sustaining unit would be one that releases its contents only in the intestine. 
       Mostly sustained-release systems currently in use the release their contents 
over the entire length of the GI tract.  Delivery systems that remains localized in a 
certain area of the GI tract and an act as reservoir for drug release are much 
advantageous for drug that not suffer from stability problems but have other 
bioavailability problems. 
4. Protein Binding: 
 Distribution of the drug into the extra vascular space is governed by the equilibrium 
process of dissociation of the drug from the protein.  The drug-protein complex can serve 
therefore as a reservoir in the vascular space for sustained drug release to extra vascular 
tissues, but only for those drugs that exhibit a high degree of binding. 
           Extensive binding to plasma proteins will be evidenced by a long half-life of 
elimination for the drug, and such drugs generally do not require a sustained-release dosage 
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form.  However, drugs that exhibit a high degree of binding to plasma proteins also might 
bind to biopolymer in the GI tract, which could have an influence on sustained drug delivery. 
           The main forces of attraction responsible for bindings are Vanderwaals forces, 
hydrogen bonding and electrostatic forces.  In general, charged compounds have a greater 
tendency to bind a protein than uncharged compounds, due to electrostatic effects.  The 
presence of a hydrophobic moiety of the drug molecule also increases its binding potential.  
Some drugs that exhibit greater than 95% binding at therapeutic levels are Amitriptyline, 
Bischydroxycoumarin, Diazepam, Diazoxide, Dicumarol, and Novobioocin.  
5. Molecular Size and Diffusivity:  
 In addition to diffusion through these biological membranes, drugs in many sustained-
release systems must diffuse through a polymeric membrane or matrix that is used to control 
their release kinetics.  The ability of a drug to diffuse through polymeric membrane or matrix 
that is used to control their release kinetics membranes is a function of its diffusivity 
(diffusion coefficient). 
 An important influence upon the value of the diffusivity, D, in polymers is the 
molecular size (or molecular weight) of the diffusing species.  In most polymers, it is possible 
to relate log D empirically to some function of molecular size. Drugs with molecular weight 
up to 500-700daltons should presence no difficulty in its regard .Drugs with intermediate 
molecular weight of 50-400 daltons, diffusivities through a flexible polymer are typically of 
the 10-8cm2sec-1 
            Log D=-SV LogV+KV=-SM LogM+KM 
Where, 
D-diffusivity, 
M-molecular weight 
V-molecular volume 
SV,SM,KV,KM=constant 
B. Biological Properties: 
1. Absorption: 
 The rate, extent and uniformity of absorption of a drug are important factors when 
considering its formulation into a sustained-release system; since the rate limiting step in 
drug delivery from a sustained-release system is its release from the dosage form, rather than 
absorption, a rapid rate of absorption of the drug relative to its release is essential if the 
system is to be successful.  The extent and uniformity of the absorption of a drug, as reflected 
by its bioavailability and the fraction of the total dose absorbed, may be quite low for a 
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variety of reasons.  This usually is not a prohibitive factor in its formulation into a sustained-
release system. 
 Some possible reasons for a low extent of absorption are poor water solubility, small 
coefficient, acid hydrolysis and metabolism, or site-specific absorption. The latter reason also 
is responsible for non-uniformity of absorption. Many of these problems can be overcome by 
an appropriately designed sustained-release system, as exemplified by the discussion under 
the potential advantages of sustained drug therapy. 
2. Distribution:  
 The distribution of a drug into vascular and extra vascular spaces in the body is an 
important factor in its overall elimination kinetics.  This, in turn, influences the formulation 
of that drug into a sustained-release system, primarily by restricting the magnitude of the 
release rate and the dose size which can be employed.  The apparent volume of distribution is 
merely proportionality constant which relates drug concentration in the blood or plasma to 
the total amount of drug in the body. 
3. Metabolism: 
             The metabolic conversion of a drug to another chemical form usually can be 
considered in the design of a sustained-release system for that drug.  As long as the location, 
rate and extent of metabolism are known and the rate constant(s) for the process are not too 
large, successful sustained-release products can be developed.  
 There are two factors associated with the metabolism of some drugs however that 
present problems of their use in sustained-release systems. One is the ability of the drug to 
induce or inhibit enzyme synthesis; this may result in a fluctuating drug blood level with 
chronic dosing.  The other is a fluctuating drug blood level due to intestinal (or other tissue) 
metabolism or through a hepatic first-pass effect.  Examples of drugs that are subject to 
intestinal metabolism upon oral dosing are Hydralazine, Salicylamide, Nitroglycerine, 
Isoproterenol, Chlorpromazine and Levodopa. Examples of drugs that undergo extensive 
first-pass hepatic metabolism are Propoxyphene, Nortriptyline, Phenacetine, Propranolol and 
Lidocaine.  
5. Elimination and Biological Half-life: 
 The rate of elimination of a drug is quantitatively described by its biological half-life, 
t1/2. The half-life of a drug is related to large release rates and large doses. At the other 
extreme, a drug with a half-life of greater than 8 hours also probably should not be used; in 
most instances, formulation of such a drug into a sustained-release system its apparent 
volume of distribution Vd and its systemic clearance. A drug with a short half-life requires 
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frequent dosing and this makes it a desirable candidate for a sustained-release formulation. 
In general, however a drug with a half-life if less than 2hours probably should not be 
used, since such systems will require unacceptably large release rates and large doses.  At the 
other extreme a drug with a half-life of greater than 8 hours also probably should not be used 
in most instances, formulation of such a drug into a sustained-release system is unnecessary. 
Some examples of drug with half-lives of less than 2 hours are Ampicillin, 
Cephalexin, Cloxacillin, Furosemide, Levodopa, Penicillin G and Propylthiouracil. Examples 
of those with half-lives of greater than 8 hours are Dicumarol, Diazepam, Digitoxin, Digoxin, 
Guanethidine, Phenytoin and Warfarin. 
5. Side effects and Safety Considerations: 
For some drugs, the incidence of side effects, in addition to toxicity, is believed to be 
related to their plasma concentration. As mentioned in the discussion on the potential 
advantages of sustained drug therapy, a sustained-release system can at times, minimize side  
over the time course of therapy. 
The most widely used measure of the margin of safety of a drug is its therapeutic index, TI, 
defined in the following equation: 
TI = TD50/ED50 
TD50 is the median toxic dose and ED50 is the median effective dose. The value of TI varies 
from as little as unity, where the effective dose is also producing toxic symptoms, to several 
thousand. For very "potent" drugs, whose therapeutic concentration range is narrow, the 
value of TI is small. In general, the larger the value of TI, the safer is the drug. Drugs with 
very small values of TI usually are poor candidates for formulation into sustained-release 
products primarily due to technological limitations of precise control over release rates. 
Examples of drugs with values of TK10 are Aprobarbital, Digitoxin, Phenobarbital and 
Digoxin. 
 6. Dose size: 
                    Sustained-release is designed to alleviate repetitive dosing, it naturally will 
contain a greater amount of drug than a corresponding conventional form. The typical 
administered dose of a drug in the conventional dosage form will give some indication of the 
total amount needed in the sustained-release preparation. For those drugs requiring large 
conventional doses, the volume of the sustained dose may be as large as that to be impractical 
or unacceptable, depending on the route of administration. The same may be true of drugs, 
which require a large release rate from the sustained-release system, e.g. drugs with short 
half-lives. 
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 The mechanisms of release from these systems can be treated in two ways: (a) 
Extraction of the medicament by a simple diffusion process through enveloping 
homogeneous matrix, (b) Leaching of the medicament by the bathing fluid, which is able to 
enter the drug-matrix phase through pores, cracks and intergranular spaces. 
When tablet ingredients are sensitive to moisture and are unable to withstand elevated 
temperature during drying and when the tablet ingredients have sufficient inherent binding or 
cohesive properties, slugging may be used to form granules. This method is known as dry 
granulation of pre-compression method or the double compression method. 
            A matrix is a uniform mixture of drug, excipients, (e.g.) polymer that is 
homogeneously fixed in a solid dosage form.  
 
1.5.2 Basic kinetics of sustain drug delivery system: 
Conventional dosage forms include solutions, suspensions, capsules, tablets, emulsions, 
aerosols, foams, ointments and suppositories. For this discuss, these dosage forms can 
be considered to release their active ingredients into an absorption pool immediately.  
This is illustrated in the following simple kinetic scheme: 
          Dosage           Kr  Absorption     Ka                   Target        Ke            
             Form       drug release    Pool            drug release Area      Elimination 
        Urine 
  
The absorption pool represents a solution of the drug at the site of absorption, and the 
terms Kr, Ka and Ke are first – order rate constants for drug release, absorption and 
overall elimination, respectively.  Immediate release from a conventional dosage form 
implies that Kr>>>Ka or that observation of drug across a biological membrane, such 
as the intestinal epithelium, is the rate-limiting step in delivery of the drug to its target 
area. 
For non immediate – release dosage form, Kr<<<Ka, that is, release of drug from the 
dosage form the rate-limiting step.   This causes the above kinetic to reduce to the 
following: 
      Dosage           Kr       Target         Ke                Urine 
  Form       drug release       Area        Elimination 
 
Non-immediate-release delivery systems may be divided conveniently into four 
categories: 
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                                 1. Delayed release 
                                 2. Sustained release 
                                          a. Controlled release 
                                          b. Prolonged release 
                                3. Site-specific release 
                                4. Receptor release 
 
       A   - Control Release Formulation 
       B - Sustain Release Formulation 
       C - Conventional Release formulation 
 
      Figure: 2. A Hypothetical plasma concentration-time profile from conventional 
                 Sustained and control delivery formula  
 
 
1.5.3 Potential Advantages of Sustained Drug Therapy: 
      1. Avoid patient compliance problems.  
      2. Employ less total drug. 
                     a. Minimise or eliminate local side effects.       
                     b. Minimise or eliminate systemic side effects. 
                     c. Obtain less potentiating or reduction in drug activity with chronic use. 
                     d. Minimise drug accumulation with chronic dosing. 
       3. Improve efficiency in treatment 
                      a.    Cure of control condition more promptly.       
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                      b.   Improve control of condition, i.e. reduce fluctuation in drug level. 
                      c.   Improve bioavailability of some drugs. 
                      d. Make use of special effects,  
         4. Economy 
 
 
1.6. SELECTION OF DRUG FOR SUSTAINED RELEASE DRUG DELIVERY 
SYSTEM: 
The choice of the drug substance is the most important decision in the successful 
development of a sustained-release product, Several categories of drug have potential for 
their therapeutics improvement of efficacy via sustained-release oral routes e.g. .Antianginal, 
Anti-inflammatory, Antihistaminic, Ant gastric resistant agents, Antipsychotic agents and 
Anti diabetic drugs of agents. 
The common goal for increased duration is twice a day, or when feasible, once a 
day. Several properties of the drug itself can lead to the achievement of a 12 to 24 hours 
oral prolonged release dosage form. Some of the characteristics militating against 
success are the following: 
1.   Very short half-life and/or a relatively large single dose. 
2.   Long half-life.  
3.   Potent drug with a low margin safety. 
4.   Poorly soluble and/or poorly absorbed. 
5.   Biological activity not a function of core in blend. 
6.   Absorption primarily active through a 'window'. 
7.   Large first-pass metabolism. 
The selection of both the drug and retardant polymers along with the filler excipients 
will impact on the mechanism and rates of drug release from monolithic systems. 
Cellulose derivatives and acrylic resin polymers comprise the group of polymers that 
are presently available as aqueous coatings for pharmaceutical dosage forms.  
 
1.7. MATRIX TABLETS: [4] 
          These are the type of controlled drug delivery systems, which release the drug 
in continuous manner. These release the drug by both dissolution controlled as well as 
diffusion controlled mechanisms. To control the release of the drugs, which are having 
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different solubility properties, the drug is dispersed in swell able hydrophilic substances, an 
insoluble matrix of rigid non swell able hydrophobic materials or plastic materials.  
 
 1.7.1. CLASSIFICATION OF MATRIX TABLETS  
A. ON THE BASIS OF RETARD MATERIAL USED IN THE MATRIX TABLET CAN BE 
DIVIDED IN TO FIVE TYPES: 
 1. Hydrophobic Matrices (Plastic matrices): 
           In this method of obtaining sustained release from an oral dosage form, drug is 
mixed with an inert or hydrophobic polymer and then compressed in to a tablet. Sustained 
release is produced due to the fact that the dissolving drug has diffused through a network of 
channels that exist between compacted polymer particles.   
Examples of materials that have been used as inert or hydrophobic matrices include 
polyethylene, polyvinyl chloride, ethyl cellulose and acryl ate polymers and their copolymers.  
The rate-controlling step in these formulations is liquid penetration into the matrix. 
The possible mechanism of release of drug in such type of tablets is diffusion. Such types of 
matrix tablets become inert in the presence of water and gastrointestinal fluid.  
    2. Lipid Matrices: 
                          These matrices prepared by the lipid waxes and related materials. Drug 
release from such matrices occurs through both pore diffusion and erosion. Release 
characteristics are therefore more sensitive to digestive fluid composition than to totally 
insoluble polymer matrix. Carnauba wax in combination with stearyl alcohol or stearic acid 
has been utilized for retardant base for many sustained release formulation.  
3. Hydrophilic Matrices: 
                         The formulation of the drugs in gelatinous capsules or more frequently, in 
tablets, using hydrophilic polymers with high gelling capacities as base excipients, is of 
particular interest in the field of controlled release. Infect a matrix is defined as well mixed 
composite of one or more drugs with a gelling agent (hydrophilic polymer). These systems 
are called swell able controlled release systems.  
4. The polymers used in the preparation of hydrophilic matrices are divided in to three 
broad groups: 
1. Cellulose derivatives: 
                 Methyl cellulose 400 and 4000cps; hydroxy ethyl cellulose; hydroxy propyl 
cellulose (HPMC) 25,100,400 and 1500 cps; Sodium car boxy methyl cellulose. 
 2. Non cellulose or semi synthetic   polymers: 
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                   Agar-agar; carob gum; alginates; molasses; polysaccharides of mannose and 
galactose; chitosan and modified starches.  
3. Polymers of acrylic acid: 
                  Corbopol 934, the most used variety.  
4. Biodegradable Matrices: 
                            These consist of the polymers which comprised of monomers linked to one 
another through functional groups and have unstable linkage in the backbone. They are 
biologically degraded or eroded by enzymes generated by surrounding living cells or by 
nonenzymetic process in to olegomers and monomers that can be metabolised or excreted.   
                    Examples are natural polymers such as proteins and polysaccharides; modified    
natural polymers; synthetic polymers such as aliphatic poly (esters) and poly anhydrides.  
5. Mineral Matrices: 
                      These consist of polymers which are obtained from various species of 
seaweeds. Example is Alginic acid which is a hydrophilic carbohydrate obtained from species 
of brown seaweeds (Phaephyceae) by the use of dilute alkali.   
B. ON THE BASIS OF POROSITY OF MATRIX: 
                         Matrix system can also be classified according to their porosity and 
consequently, macro porous; micro porous and non-porous systems can be identified:  
1. Macro porous Systems: 
                          In such systems the diffusion of drug occurs through pores of matrix, which 
are of size range 0.1 to 1 μm. This pore size is larger than diffusant molecule size.  
2. Micro porous System: 
                           Diffusion in this type of system occurs essentially through pores. For micro 
porous systems, pore size ranges between 50 – 200 A°, which is slightly larger than diffusant 
molecules size.  
3. Non-porous System: 
                           Non-porous systems have no pores and the molecules diffuse through the 
network meshes. In this case, only the polymeric phase exists and no pore phase is present.  
 
1.7.2. ADVANTAGES OF MATRIX TABLET: 
              1. Easy to manufacture  
              2. Versatile, effective and low cost  
              3. Can be made to release high molecular weight compounds. 
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 1.7.3 DISADVANTAGES OF THE MATRIX SYSTEMS: 
                        The remaining matrix must be removed after the drug has been released. The 
drug release rates vary with the square root of time. Release rate continuously diminishes due 
to an increase in diffusional resistance and/or a decrease in effective area at the diffusion 
front. However, a substantial sustained effect can be produced through the use of very slow 
release rates, which in many applications are indistinguishable from zero-order.  
 
1.8. POLYMERS USED IN MATRIX TABLETS: 
 Hydro gels 
Polyhydroxyethyle methylacrylate (PHEMA) 
Cross-linked polyvinyl alcohol (PVA) 
Cross-linked polyvinyl pyrrolidone (PVP) 
Polyethylene oxide (PEO) 
Polyacrylamide (PA) 
 Soluble polymers 
Polyethylene glycol (PEG)  
Polyvinyl alcohol (PVA)  
Polyvinyl pyrrolidone (PVP)  
Hydroxypropyl methyl cellulose (HPMC)  
Biodegradable polymers 
Polylactic acid (PLA)  
Polyglycolic acid (PGA)  
Polycaprolactone (PCL)  
Polyanhydrides  
Polyorthoesters  
 Nonbiodegradable polymers 
Polyethylene vinyl acetate (PVA)  
Polydimethyl siloxane (PDS)  
Polyether urethane (PEU)  
Polyvinyl chloride (PVC)  
Cellulose acetate (CA)  
Ethyl cellulose (EC)  
Hydroxy propyl methyl cellulose (HPMC) 
  Mucoadhesive polymers 
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Polycarbophil  
Sodium carboxymethyl cellulose  
Polyacrylic acid  
Tragacanth  
Methyl cellulose  
Pectin 
Sodium alginate   
    Natural gums 
Xanthans gum  
Guar gum  
Karaya gum 
  
1.9. DRUG RELEASE FROM MATRIX SYSTEMS:[5] 
                       Drug in the outside layer exposed to the bathing solution is dissolved first and 
then diffuses out of the matrix. This process continues with the interface between the bathing 
solution and the solid drug moving toward the interior. It follows that for this system to be 
diffusion controlled, the rate of dissolution of drug particles within the matrix must be much 
faster than the diffusion rate of dissolved drug leaving the matrix.  
1.9.1 DERIVATION OF THE MATHEMATICAL MODEL TO DESCRIBE THIS SYSTEM INVOLVES 
THE FOLLOWING ASSUMPTIONS: 
a) A pseudo-steady state is maintained during drug release;  
b) The diameter of the drug particles is less than the average distance of drug diffusion 
through the matrix;  
d) The bathing solution provides sink conditions at all times.  
The release behaviour for the system can be mathematically described by the following 
equation:  
                           dM/dh = Co. dh - Cs/2 -------------  1                                      
          Where  
                          DM = Change in the amount of drug released per unit area  
                           dh = Change in the thickness of the zone of matrix that has                        
been depleted of drug  
                     Co = Total amount of drug in a unit volume of matrix  
                     Cs = Saturated concentration of the drug within the matrix.  
 Additionally, according to this theory          
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                          dM = ( Dm . Cs / h).  dt ------------- 2 
Where:  
                       Dm = Diffusion coefficient in the matrix.  
                        h = Thickness of the drug-depleted matrix  
                      dt = Change in time  
By combining equation 1 and equation 2 and integrating:  
                       M=[Cs.Dm.(2Co−Cs).t]½-------------3                                                           
 When the amount of drug is in excess of the saturation concentration, then:  
                       M = [2Cs. Dm . Co .  t] ½-------------4 
     Equation 3 and equation 4 relate the amount of drug release to the square-root of time. 
Therefore, if a system is predominantly diffusion controlled, then it is expected that a plot of 
the drug release vs. square root of time will result in a straight line. Drug release from a 
porous monolithic matrix involves the simultaneous penetration of surrounding liquid, 
dissolution of drug and leaching out of the drug through tortuous interstitial channels and 
pores. The volume and length of the openings must be accounted for in the drug release from 
a porous or granular matrix:  
                       M = [Ds.Ca.p/T. (2Co – p.Ca) t]1/2-------------5 
Where:  
                                          p = Porosity of the matrix  
                                          t = Tortuosity  
                                           Ca = solubility of the drug in the release medium  
                                           Ds = Diffusion coefficient in the release medium.  
                                           T = Diffusional pathlength 
  For pseudo steady state, the equation can be written as:  
                       M= [2D.Ca.Co(p/T)t]1/2  -------------6 
The total porosity of the matrix can be calculated with the following equation:  
                         p=pa+Ca/ρ+Cex/ρex -------------7 
Where:  
                                  p = Porosity  
                                  ρ = Drug density  
                                 pa = Porosity due to air pockets in the matrix  
                                 ρex = Density of the water soluble excipients  
                                Cex = Concentration of water soluble excipients  
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For the purpose of data treatment, equation 7 can be reduced to:  
                         M=k.t1/2-------------8 
Where k is a constant, so that the amount of drug released versus the square root of 
time will be linear, if the release of drug from matrix is diffusion-controlled. If this is the 
case, the release of drug from a homogeneous matrix system can be controlled by varying the 
following parameters 
• Initial concentration of drug in the matrix  
• Porosity  
• Tortuosity  
• Polymer system forming the matrix  
• Solubility of the drug.  
 
1.8.2 BIMODAL RELEASE: 
           In certain systems there is a bimodal or anomalous release of the active 
ingredient. In these systems there is diffusion; additionally, the extended release polymer may 
become hydrated and begin to dissolve leading to release upon erosion. These systems are 
complex and difficult to mathematically model since the diffusional path length undergoes 
change due to the polymer dissolution.  
A series of transport phenomena are involved in the release of a drug from a swellable, 
diffusion/erodable matrix:  
a) Initially, there are steep water concentration gradients at the polymer/water interface, 
resulting in absorption of water into the matrix.  
b) Due to the absorption of water, the polymer swells, resulting in dramatic changes of drug 
and polymer concentration, increasing the dimensions of the system and increasing 
macromolecular mobility.  
c) Upon contact with water the drug dissolves and diffuses out of the device.  
d) With increasing water content, the diffusion coefficient of the drug increase substantially.  
e) In the case of a poorly water-soluble drug, dissolved and undissolved drug coexist within 
the polymer-matrix  
f) Finally, the polymer self dissolves.  
1.9.3 THESE SYSTEMS ARE DESCRIBED IN TERMS OF FRONTS. THE FOLLOWING FRONTS 
HAVE BEEN DEFINED, WITH REGARD TO ANOMALOUS RELEASE SYSTEMS:[6] 
• The “swelling front”, the erosion front, and the diffusion front. The swelling front 
separates the rubbery region (swelling polymer area) which has enough water absorbed 
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within the polymer to lower the Tg of the polymer below the respective environmental 
temperature allowing for macromolecular mobility and swelling, from the non-swelling 
polymer region (where the polymer exhibits a Tg that is above the respective environmental 
temperature).  
• The “erosion front” separates the matrix from the bulk solution and is the interface 
between the unstirred layer with polymer concentration gradient and the well stirred medium.  
• The “diffusion front” is between the swelling and erosion front and separated the 
areas of non dissolved drug from the area of dissolved drug.  
With regard to swelling matrix systems, alternate models have been proposed to describe the 
diffusion, swelling, and dissolution processes occurring with into the system and these 
phenomena lead to drug release.  
The gel strength is important in the matrix performance and is controlled by the 
concentration, viscosity and chemical structure of the rubbery polymer. This restricts the 
suitability of the hydrophilic polymers for preparation of swellable matrices. Polymers such 
as carboxymethylcellulose, hydroxypropylcellulose or tragacanth gums do not form the gel 
layer quickly. Consequently, they are not recommended as excipients to be used alone in 
swellable matrices.  
In 1985 Peppas introduced a semi-empirical equation describing the drug release 
behaviour from anomalous-release, hydrophilic matrix systems:  
                                      Q = k. t n -------------9 
Where:  
                              Q = Fraction of drug release in time (t)  
                              t = Time  
                              k = Rate constant (incorporates of polymer system and drug)  
                              n = Diffusional exponent  
The value of n is indicative of the drug release mechanism.  
In order to describe relaxational transport, then modified equation 9 in order to account for 
relaxational transport:  
                                  Q = k1 . tn + k2 . t 2 n-------------10 
 Where:  
                     k1 =Fickain diffusion constant 
                     k2 = Relaxtional mechanism constant  
If the surface area of the system is fixed, which is unlikely, the value of n should be 0.5 and 
equation 10 is transformed to:  
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                                  Q = k1. t0.5 + k2. t-------------11 
     The first term of this equation accounts for diffusional phenomena, while the second term 
of this equation accounts for potote have been utilized in matrix type tablet formulations  
 
1.10. EFFECT OF RELEASE LIMITING PARAMETER ON DRUG RELEASE: 
                          The analysis of controlled release of drug reveals that partition coefficient; 
diffusivity; diffusional path thickness and other system parameters play various rate 
determining roles in the controlled release of drugs from either capsules, matrix or sandwich 
type drug delivery systems.[7] 
A .Polymer hydration:  
                         It is important to study polymer hydration/swelling process for the maximum 
number of polymers and polymeric combinations. The most important step in polymer 
dissolution include absorption/adsorption of water in more accessible places, rupture of 
polymer-polymer linking with the simultaneous forming of water-polymer linking, separation 
of polymeric chains, swelling and finally dispersion of polymeric chain in dissolution 
medium.  
B .Drug solubility:  
                         Molecular size and water solubility of drug are important determinants in the 
release of drug from swelling and erosion controlled polymeric matrices. For drugs with 
reasonable aqueous solubility, release of drugs occurs by dissolution in infiltrating medium 
and for drugs with poor solubility release occurs by both dissolution of drug and dissolution 
of drug particles through erosion of the matrix tablet.  
C .Solution solubility:  
                            In view of in vivo (biological) sink condition maintained actively by 
hemoperfusion; it is logical that all the in vitro drug release studies should also be conducted 
under perfect sink condition. In this way a better simulation and correlation of in vitro drug 
release profile with in vivo drug administration can be achieved. It is necessary to maintain a 
sink condition so that the release of drug is controlled slowly by the delivery system and is 
not affected or complicated by solubility factor.  
D .Polymer diffusivity: 
                             The diffusion of small molecules in polymer structure is energy activated 
process in which the diffusant molecules moves to a successive series of equilibrium position 
when a sufficient amount of energy of activation for diffusion Ed has been acquired by the 
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diffusant is dependent on length of polymer chain segment, cross linking and crystallinity of 
polymer. The release of drug may be attributed to the three factors viz,  
 
1) Polymer particle size  
2) Polymer viscosity  
3) Polymer concentration.  
I. Polymer particle size:  
                            Malamataris stated that when the content of hydroxypropyl methylcellulose 
is higher, the effect of particle size is less important on the release rate of propranolol 
hydrochloride, the effect of this variable more important when the content of polymer is low. 
He also justified these results by considering that in certain areas of matrix containing low 
levels of hydroxypropyl methylcellulose led to the burst release.  
II. Polymer viscosity: 
                               With cellulose ether polymers, viscosity is used as an indication of matrix 
weight. Increasing the molecular weight or viscosity of the polymer in the matrix formulation 
increases the gel layer viscosity and thus slows drug dissolution. Also, the greater viscosity of 
the gel, the more resistant the gel is to dilution and erosion, thus controlling the drug 
dissolution.  
III. Polymer concentration:  
                                   An increase in polymer concentration causes an increase in the 
viscosity of gel as well as formulation of gel layer with a longer diffusional path. This could 
cause a decrease in the effective diffusion coefficient of the drug and therefore reduction in 
drug release. The mechanism of drug release from matrix also changes from erosion to 
diffusion as the polymer concentration increases.  
E. Thickness of polymer diffusional path: 
                             The controlled release of a drug from both capsule and matrix type 
polymeric drug delivery system is essentially governed by Fick’s law of diffusion: 
JD=Ddc/dx 
JD flux of diffusion across a plane surface of unit area where D is diffusibility of drug 
molecule, dc/dx is concentration gradient of drug molecule across a diffusion path with 
thickness dx.  
 F .Thickness of hydrodynamic diffusion layer: 
                             It was observed that the drug release profile is a function of the variation in 
thickness of hydrodynamic diffusion layer on the surface of matrix type delivery devices. The 
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magnitude of drug release value decreases on increasing the thickness of hydrodynamic 
diffusion layer δd. 
H .Drug loading dose: 
                              The loading dose of drug has a significant effect on resulting release 
kinetics along with drug solubility. The effect of initial drug loading of the tablets on the 
resulting release kinetics is more complex in case of poorly water soluble drugs, with 
increasing initial drug loading the relative release rate first decreases and then increases, 
whereas, absolute release rate monotonically increases.  
 In case of freely water soluble drugs, the porosity of matrix upon drug depletion increases 
with increasing initial drug loading. This effect leads to increased absolute drug transfer rate. 
But in case of poorly water soluble drugs another phenomenon also has to be taken in to 
account. When the amount of drug present at certain position with in the matrix, exceeds the 
amount of drug soluble under given conditions, the excess of drug has to be considered as 
non dissolved and thus not available for diffusion. The solid drug remains with in tablet, on 
increasing the initial drug loading of poorly water soluble drugs, the excess of drug remaining 
with in matrix increases.  
I .Surface area and volume:  
                             The dependence of the rate of drug release on the surface area of drug 
delivery device is well known theoretically and experimentally. Both the in vitro and in vivo 
rate of the drug release, are observed to be dependent upon surface area of dosage form. 
Siepman et al. found that release from small tablet is faster than large cylindrical tablets.  
J. Diluent’s effect:  
                         The effect of diluent or filler depends upon the nature of diluent. Water 
soluble diluents like lactose cause marked increase in drug release rate and release 
mechanism is also shifted towards Fickian diffusion; while insoluble diluents like dicalcium 
phosphate reduce the Fickian diffusion and increase the relaxation (erosion) rate of matrix. 
The reason behind this is that water soluble filler in matrices stimulate the water penetration 
in to inner part of matrix, due to increase in hydrophilicity of the system, causing rapid 
diffusion of drug, leads to increased drug release rate.  
K. Additives:  
                          The effect of adding non-polymeric excipients to a polymeric matrix has 
been claimed to produce increase in release rate of hydro soluble active principles. These 
increases in release rate would be marked if the excipients are soluble like lactose and less 
important if the excipients are insoluble like tricalcium phosphate. 
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2. LITERATURE REVIEW: 
 
1. K.SREENIVASA RAO et al 2011, studied development and evaluation of sustained 
release formulation of Venlafaxine hydrochloride by choosing it as a suitable candidate for 
sustain matrix tablet formulation. The drug was formulated into matrix tablet using 
hydrophilic polymer such as HPMC, Eudragit RS100 and ethyl cellulose as release 
retardants. Matrix tablet content a blend of HPMC and ethyl cellulose successfully sustained 
the release of Venlafaxine for a period of 17hrs.Venlafaxine F4 showed the sustained release 
of Venlafaxine as desired.[8] 
  
2. KANIKA GOYAL et al  2009,  studied formulation and evaluation of once-daily  
sustained release Venlafaxine hydrochloride tablet using hydrophilic matrix using 
hydrophilic gums and polymers such as Xanthan [Xgum], Guar gum [Ggum] and HPMC as a 
release modifier. The tablets are prepared by direct compression method. Xanthan gum along 
with HPMC K15M showed the sustained release of the drug for 20hrs.[9] 
 
3. MC GOHEL et al 2009, studied modulation of Venlafaxine hydrochloride release from 
press coated matrix tablet by using HPMC K4M and HPMC K100M as release modifier in 
core and coat respectively. The kinetics of drug release was explained by Korsmeyer and 
Peppas model(anomalous non-Fickian diffusion).The systemic formulation approach enabled 
us to develop modified release Venlafaxine hydrochloride tablet.[10] 
 
4. ASHWINI.R et al 2009. studied the design of sustained release matrix tablets of 
Venlafaxine hydrochloride using ion exchange resin with the incorporation of hydrophilic 
and hydrophobic polymer combinations. Validation of optimization study performed using 
five confirmatory runs, indicated very high degree of prognostic ability of response surface 
methodology .HPMC and ethyl cellulose can successfully employed as a once-a- day oral 
controlled release drug delivery system .[11] 
 
5. ALTUL A.BODKHE et al 2008 designed extended release tablet of Venlafaxine 
hydrochloride using hydrophobic matrix. Matrix system based on non swell able was selected 
for sustaining the drug release. Different polymers and waxes viz. HPMC, stearic acid, acetyl  
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alcohol, ethyl cellulose etc. were used. Combinations of non swellable waxes with HPMC 
were also tried in order to get the desired sustained release profile over a period of 24hrs.[12] 
 
6. SENTHILNATHAN et al 2011 developed Venlafaxine hydrochloride orodispersible 
tablet by using conventional technique such as superdisintegrant technology. Trails were 
conducted for the selection of superdisintegrant. In this sodium starch glycolate and 
crosscarmellose sodium are used in the rapid disintegration of tablets. The stability study was 
conducted for the optimized batch.[13] 
. 
7. LADANI ANIKET et al 2011, studied fabrication of multi-layer matrix tablets of 
Venlafaxine hydrochloride using Hypromellose (HPMC K100M) and Xanthan gum. The 
tablets containing Venlafaxine hydrochloride 150mg were prepared using hybrid wet 
granulation barrier layer technology, using HPMC K100M as rate controlling ingredient in 
the middle layer and Xanthan gum in barrier layers. Drug release kinetic of the optimized 
triple layered tablets best fits to Higuchi model where as the release exponent value obtained 
for Korsmeyer Peppas model was less than 0.45, which is beyond the limit of the model. 
Release mechanism appears to be complex mechanism of swelling, diffusion, erosion and 
barrier controlled.[14] 
 
8. BINDU MADHAVI B et al 2011, studied formulation and evaluation of Venlafaxine 
hydrochloride microspheres. The microspheres were prepared by emulsification and solvent 
evaporation method. The polymer used is ethyl cellulose. Drug polymer compatibility is done 
by FTIR studies. The method had resulted in good encapsulation efficiency and micron sized 
ethyl cellulose microspheres. The drug release was found to be sustained for 16hrs and 
follows Peppas kinetics.[15] 
 
9. ZULKARNAIN KAMAL MOHAMMAD et al 2010 investigated the formulation and 
evaluation of mucoadhesive microspheres of Venlafaxine hydrochloride by using carbopol 
and HPMC K4M as mucoadhesive polymer. There was a sustained release up to 12hrs and 
almost 70% of mucoadhesion was observed after 12hrs.[16] 
 
10. A.RAVINDRANATH et al 2010, studied formulation and evaluation of Venlafaxine 
hydrochloride enclosed in alginate micro beads prepared by Iontophoretic gelation method.  
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The micro beads were prepared by isotropic gelation of sodium alginate in calcium chloride 
solution. The method has resulted in good encapsulation efficiency and micron sized alginate 
 spheres. The drug release was found to be sustained for 16hrs and follows Korsmeyer and 
Peppas kinetics.[17] 
11. ADIMOOLAM SENTHIL et al 2011, investigated to formulate and evaluate the 
mucoadhesive Venlafaxine hydrochloride microspheres HPMC K4M as polymer. 
Microspheres were prepared by simple emulsification phase separation technique using 
glutaraldehyde as a cross linking agent. The drug polymer compatibility studies were carried 
out by FTIR.As the concentration of glutaraldehyde increased the mucoadhesiveness 
decreases an there was no significant effect in time. Stirring speed has negative effect on 
t80.[18] 
 
12. SOURABH JAIN et al 2008, studied preparation and evaluation of sustain release tablet 
of Furosemide using natural polymers such as Pectin, Guar gum and Xanthan gum .The tablet 
with guar gum have the greatest swelling index those than pectin and Xanthan gum. A better 
controlled drug release was obtained about (80.74%) approximately in15 hrs using this 
natural polymers.[19] 
 
13.RAGHAVENDRA RAO.N et al 2009, studied the development of sustain release matrix 
tablets of water soluble Tramadol hydrochloride using different polymers viz,HPMC and 
natural gums like karaya gum(KG) and carrageenan(CG). Among all the formulations, 
formulation F16 which contains 20% HPMC K15M and 80% of CG release the drug which 
follow Zero order kinetics via, swelling, diffusion and erosion and the release profile of 
formulation F16 was comparable with the marketed product. Stability studies 
(40±2ºC/75±5%RH) for 3 months indicated that Tramadol hydrochloride was stable in the 
matrix tablets. The DSC and FTIR study revealed that there was no chemical interaction 
between drug and excipient.[20] 
 
14.V.MURUGANATHAN,SANDIP et al 2009,investigated the increase of therapeutic 
efficacyto reduce frequency of administration and improve patient compliance, by developing
 sustained release Zidovudine using different drug polymer ratio. Kollidon SR, Hydroxypropy
l methylcellulose K15M, K100Mas matrix former.Among the different formulation B8 showe
d sustained release of drug for 12 hours with  86.55% release. The regression coefficient  
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value of  Higuchi  plot  was  found  to  be  0.9925   that   showed  that  drug  was  released   
by diffusion  mechanism.  The  slope  value  of  korsmeyer  ‐  peppas  equation  was  found to 
be 0.5062 which indicating that drug was released by non-Fickain release mechanism.The R2 
value indicates that drug release was limited by drug particle dissolution rate and erosion of 
thepolymer.Thus, drug in combination with Hydroxypropyl methylcellulose K100M were fou
nd to be effective in retarding the release of Zidovudine.[21] 
 
15. AFSAR C.SHAIKH et al 2009, studied to develop “once daily” sustained   
release tablets of Aceclofenac (200mg) by wet granulation using hydrophilic polymer like Hy
droxy propyl methyl cellulose K ‐100M. FTIR studies shown there was no interaction betwee
n drug and polymer.  The drug release from optimized formulations was extended for a perio
d of 4 hrs. The kinetic treatment of selected formulation (F8) showed that the release of drug 
follows zero order models. The optimized formulations were subjected to stability studies for 
one month at 45° temperature with RH 75±5% and showed there were no significant changes 
in drug content, physicochemical parameters and release pattern. Hydrophilic polymers in the
 preparation of matrix based sustained release formulation of Aceclofenac .[22]  
 
16. SH LAKADE et al 2008, studied to develop hydrophilic polymer (HPMC) and 
hydrophobic polymer (Ethyl cellulose) based Nicorandil matrix sustained release tablet which 
can release the drug up to time of 24 hrs in predetermined rate. The influence of hydrophilic 
and hydrophobic polymer and granulation technique on Nicorandil was studied. The 
formulated tablet were also characterized by physical and chemical parameters, The in-vitro 
release rate profile should the higher concentration of F2 polymer in tablet, the combination 
of hydrophilic and hydrophobic combination showed less result than use of alone. This 
formulation follows Peppas and Hixon crowel release kinetics.[23] 
 
17. MD SHAID ALI et al 2010 studied to develop sustained release matrix tablets of 
Phenytoin sodium an antiepileptic drug. The tablets were fabricated by the wet granulation 
method using water as granulating agent along with matrix materials like guar gum, sodium 
alginate, tragacanth and xanthan gum with varying percentage. The I.R spectral analysis 
.studies confirmed no interaction between phenytoin with used natural gums. The formulation 
development process, F8 (55% guar gum with 10% acacia), the most successful formulation. 
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of the study, exhibited satisfactory drug release and could extend the release up to 12 hours. 
The mechanism of drug release from all the formulations was diffusion coupled 
witherosio.[24] 
  
18. KALYANI CHITALURI et al 2011,sustaine release matrix tablets of Lostran potassium 
using Eudragit RLPO,RSPO and Ethyl cellulose individually and in combination. These 
matrix tablets were prepared by direct compression method. Drug-Excipient interaction was 
evaluated by differential scanning calorimetry and FTIR .The tablets prepared data shows 
individual concentration of RLPO,RSPO sustain the drug up to 10 hrs, with ethyl cellulose 
sustain the drug more than 12 hrs, Eudragit release the drug up to 12 hrs. The kinetics of drug 
release fallows Fickain diffusion mechanism.[25] 
 
19. GANESH KUMAR et al 2010, studied Formulation and evaluation Monolithic matrix 
tablet of Acarbose using Hydroxypropyl methylcellulose and Eudragit in different 
concentration and combination, and sustained release behavior the fabricated tablets were 
investigated. Tablet prepared by direct compression method Standard curve and withdrawal 
samples were analyzed in UV-Vis spectrophotometery 625nm with alkaline potassium 
permanganate as coloring agent. formulations F1, F2, F3 wherein Hydroxypropyl 
methylcellulose K 100 M was employed, it was found that increasing the concentration of the 
polymer resulted in linearization of drug release curve and formulation F3 gave satisfactory 
drug release pattern. Formulations F4, F5, F6 containing Eudragit S-100 showed quite non-
linearity in drug release. To analyze drug release mechanism Zero order, Higuchi model and 
Kosmeyer-peppas model were used.[26] 
 
20. R MARGRET CHANDIRA et al 2010, studied to formulate and evaluate once daily 
extended release matrix tablets of Mirtazapine an atypical anti-depressant used in major 
depressive disorder. Alcoholic solution of povidone was used as granulating agent and 
hydrophilic matrix materials like Hydroxyl Propyl Methyl Cellulose, Poly Ethylene Oxide, 
and Carbopol were used as release controlling agents. The tablets were subjected to studies of 
thickness, hardness, weight variation, friability and in vitro release. According to theoretical 
release profile calculation, a once daily extend release formulation should release the 1.9 mg 
of Mirtazapine in 1 hour (6.88 % per hour). The results of dissolution studies indicated that 
formulation T-13 released the drug up to 14 hours in a zero order manner, and total release 
pattern was very close to the theoretical release profile.[27] 
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21. ROSHANPRADHAN et al 2010,a Hydroxypropyl methyl cellulose (HPMC K4M, 
HPMC K15M, and HPMC K100M) matrix tablet containing Indomethacin along with 
mannitol was formulated as a function of HPMC viscosity, and was compared with  the  
commercial products.. The formulated products and two marketed products as reference 
sample were studied for its different physicochemical parameters and in vitro dissolution 
studies. It was found that the drug release profile decreases with increase in viscosity of 
polymer and, with increase polymer level in the formulations. Matrix tablets formulated 
employing drug: HPMCK15M: mannitol l: 1:0.25:1 and Drug: HPMC K15M: mannitol 1: 
1:0.25:2 gave slow release of Indomethacin spread over 12 hours and their dissolution 
profiles were compared with the Indian marketed product.[28] 
 
22. IZHAR AHMED SYED et al 2011, studied matrix and triple layer matrix tablets of 
metoprolol tartrate were formulated by using xanthan gum as the matrix forming agent and 
Sodium Carboxy Methyl Cellulose (Na CMC) as barrier layers. Mean dissolution time 
(MDT) for M3 and M3L3 were found to be 4.02h and 12.75h, while dissolution efficiency 
(DE8%) decreased, indicating that the release of metoprolol tartrate is slower from triple 
layer matrix tablets. The finding of the study indicated that the matrix tablets prolonged the 
release, but predominantly in a first order kinetics. Layering with Na CMC granules on the 
matrix core, provided linear drug release with zero order kinetics. FT-IR and DSC studies 
confirmed that there was no chemical interaction between drug and excipients used in the 
formulation.[29] 
 
23. PADMASREE et al 2011, investigated effervescent floating matrix tablet of Famotidine 
are formulated to achieve gastric retention for a period 8-10 hrs. Natural polymers such as 
Xanthan gum and Chitosan were used to sustain release of the drug .Thus one tablet daily is 
sufficient to reduce gastric acidity as compared to conventional tablets of hyperacidity 
condition.[30] 
 
24. CHADRAN. S et al 2008, studied Design and evaluation of ethyl cellulose based matrix 
tablets of ibuprofen with pH modulated release kinetics. It was found that with increasing the 
proportion of ethyl cellulose in the matrix, the drug release was extended for 14-16 h. 
Incorporation of cellulose acetate phthalate in ethyl cellulose matrix provided very low initial 
release of the drug in the first 2-3 h followed by enhanced release rate in alkaline medium  
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owing to the high solubility of cellulose acetate phthalate at basic pH which led to creation of 
a porous matrix. It was found that with increasing the proportion of ethyl cellulose in the 
matrix for drug release was extended for 14-16 h. Incorporation of cellulose acetate phthalate 
in ethyl cellulose matrix provided very low initial release of the drug in the first 2-3 h 
followed by enhanced release rate in alkaline medium owing to the high solubility of 
cellulose acetate phthalate at basic pH which led to creation of a porous matrix.[31] 
  
25. A MESNUKUL et al 2009, studied to fabricate the polyethylene glycol matrix tablet by 
mould technique. Indomethacin and HPMC were used as model drug and polymer in PEG 
matrix. The rate of drug release of tablet by using conventional technique such as 
superdisintegrant technology. Trails were conducted for the selection of superdisintegrant. In 
this sodium starch glycolate and crosscarmellose sodium are used in the rapid disintegration 
of tablets. The stability study was conducted for the optimized batch.[32] 
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3. AIM AND OBEJECTIVE: 
     Venlafaxine hydrochloride is an anti depressant drug 
                          The main objectives of this study is to check the selected polymer’s sustained 
drug delivery efficacy. 
        
 
               The primary goal of sustained drug delivery system is to reduce dosing frequency 
and enhance the drug absorption process in a specific manner in order to increase the half-life 
of the drug. The purpose of this research is to design and develop matrix tablet of 
Venlafaxine hydrochloride to sustain or control release of drug, which may reduce sudden 
peak levels of drug in blood  
 
   In summary, Venlafaxine hydrochlorides higher solubility in water results  burst effect with 
sudden peak levels of drug in blood .By matrix formulation of the drug  we can minimize the 
cost with patient compliance. 
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4. PLAN OF WORK:  
                               1. Literature survey 
                               2. Preformulation studies  
                               3. Selection of Excipients 
                               4. Formulation optimizations studies 
                               5. In - vitro drug release studies 
                               6. Statistical data analysis  
 STAGE 1:  
 Literature Review  
                       Literature search is in done by various national and international journals.  
 STAGE 2: 
 Preformulation study 
                     1. Development of calibration curve for Venlafaxine hydrochloride 
                     2. Compatibility studies between drug & other additives 
                     3. Drug excipient interaction study-FTIR 
 STAGE 3: 
 Formulation & evaluation of tablets 
                    1. Preparation of Venlafaxine hydrochloride matrix tablet 
                      2. To study the effect of certain process/formulation variables on the       
physicochemical and in vitro behaviour. 
                    3. Evaluation of tablet for: 
                                a. Weight variation 
                                b. Hardness 
                                c. Friability 
                                d. Drug content assay 
                                f. In vitro Dissolution test 
                                e. Data model fitting  
 STAGE 4: Stability study. 
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5. DRUG PROFILE: 
 
5.1 VENLAFAXINE HYDROCHLORIDE: 
   Synonyms: Effexor, Effexor XR 
   Chemical structure: 
 
                                           
                                                            FIGURE NO :3 CHEMICAL STRUCTURE  
 
The chemical structure of venlafaxine is designated (R/S)-1-[2-(dimethylamino)-1-(4 
methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[a [a- (dimethylamino)methyl] 
p-methoxybenzyl] cyclohexanol hydrochloride 
 
Empircal formula : C17H27NO2 
Mol. Mass :277.402g/ml 
Pharmacokinetic data  
Bioavailability : 45% 
Protein binding: 27% 
Metabolism  : hepatic 
Half-life         : 5±2h, 
Excretion       : renal 
Physical/chemical properties: 
   Colour: It is a white to off-white crystalline powder. 
   Odour: no odour. 
   Taste: slightly bitter in taste 
   Solubility: It is freely soluble in and chloroform. In soluble in ether 
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Mechanism of action: 
                                          Venlafaxine is a bicyclic antidepressant, and is usually categorized 
as a serotonin-norepinephrine reuptake inhibitor (SNRI), but it has been referred to as a 
serotonin-norepinephrine-dopamine reuptake inhibitor.[33,34] It works by blocking the 
transporter "reuptake" proteins for key neurotransmitters affecting mood, thereby leaving 
more active neurotransmitters in the synapse. The neurotransmitters affected are serotonin (5-
hydroxytryptamine) and norepinephrine (noradrenalin). Additionally, in high doses it weakly 
inhibits the reuptake of dopamine, with recent evidence showing that the norepinephrine 
transporter also transports some dopamine as well, implying that SNRIs may also increase 
dopamine transmission. This is because SNRIs work by inhibiting reuptake, i.e. preventing 
the serotonin and norepinephrine transporters from taking their respective neurotransmitters 
back to their storage vesicles for later use. If the norepinephrine transporter normally recycles 
some dopamine too, then SNRIs will also enhance dopaminergic transmission. However, 
while concurrent increase in dopamine (particularly in the prefrontal cortex) is likely to occur 
[50], the antidepressant effects of any drug are believed to result largely from the modulation 
of serotonin and norepinephrine; dopamine is thought to play a comparatively small role in 
depression. 
  
Approved:  
                     Venlafaxine is used primarily for the treatment of major depression, generalized 
anxiety disorder, social anxiety disorder, obsessive–compulsive disorder, panic disorder, and 
menopausal hot flashes in adults.  
 
Depression: 
                  Multiple double blind studies show venlafaxine's effectiveness in treating 
depression. Venlafaxine has similar efficacy to the tricyclic antidepressants amitriptyline 
(Elavil) and imipramine and is better tolerated than amitriptyline. Its efficacy is similar to or 
better than sertraline (Zoloft) and fluoxetine (Prozac), depending on the criteria and rating 
scales used. Higher doses of Venlafaxine are more effective, and more patients achieved 
remission or were "very much improved". The efficacy was similar if the number of patients 
who achieved "response" or were "improved" was considered. A meta-analysis comparing 
Venlafaxine and combined groups of SSRI or tricyclic antidepressants showed venlafaxine's 
superiority. Judged by the same criteria, Venlafaxine was similar in efficacy to the atypical 
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antidepressant bupropion (Wellbutrin); however, the remission rate was significantly lower 
for Venlafaxine In a double-blind study, patients who did not respond to an SSRI were 
switched to Venlafaxine or citaloprarm. 
 
Drug interactions: 
 
                            Venlafaxine should be taken with caution when using St John's wort 
Venlafaxine may lower the seizure threshold, and co-administration with other drugs that 
lower the seizure threshold such as bupropion and tramadol should be done with caution and 
at low doses .[35] There have been false positive phencyclidine (PCP) results caused by 
Venlafaxine with certain on-site routine urine-based drug tests. Although the synergistic 
effects may not be as bad as with other anti-depressants, it is still not recommended to take 
Venlafaxine with alcohol.                                                                                                                                     
 
Common side effects: 
                           Headache (34%) 
                Nausea (21-35%) 
                Insomnia (15-23%) 
                Sexual dysfunction (14-34%) 
                Dry mouth (12-16%) 
                Dizziness (11-20%) 
                Sweating (10-14%) 
                Decreased Appetite (8-20%) 
                Abnormal ejaculation (8-16%) 
                Hypertension (4-5%) 
                Vivid/Abnormal dreams (3-7%) 
                Akathisia (Agitation) (3-4%) 
                Decreased libido (3-9%) 
                Increased yawning (3-5%) 
                Apathy 
               Constipation 
               Increased anxiety at the start of treatment 
               Drowsiness 
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Increased anxiety at the start of treatment 
              Drowsiness 
 
Dose dependency of adverse events: 
                                                           A comparison of adverse event rates in a fixed-dose 
study comparing Venlafaxine 75, 225, and 375 mg/day with placebo revealed a dose 
dependency for some of the more common adverse events associated with venlafaxine use. 
The rule for including events was to enumerate those that occurred at an incidence of 5% or 
more for at least one of the Venlafaxine groups and for which the incidence was at least twice 
the placebo incidence for at least one Venlafaxine group. Tests for potential dose 
relationships for these events (Cochran-Armitage Test, with a criterion of exact 2-sided p-
value <=0.05) suggested a dose-dependency for several adverse events in this list, including 
chills, hypertension, anorexia, nausea, agitation, dizziness, somnolence, tremor, yawning, 
sweating, and abnormal ejaculation. 
  
Memory loss: 
                       In a study of 70 patients that compared the tolerability of Venlafaxine at 
standard doses, ranging from 75 to 300 mg, against relatively high doses (rarely prescribed), 
ranging from 375 to 600 mg per day, for treating DSM-IV major depressive disorder "failing 
memory" was reported in 44% of cases. The severity of Venlafaxine-induced memory loss 
was also noted to increase with dose and length of treatment.  
 
Over dosage:  
                       Overdosing with the drug can result in cardiac arrhythmia, hypotension, 
seizures, coma or even death. Plasma Venlafaxine concentrations in overdose survivors have 
ranged from 6-24 mg/l, while post-mortem blood levels in fatalities are often in the 10-90 
mg/l range. 
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6. EXICIPIENT PROFILE:[36] 
6.1 HYDROXY PROPYL METHYL CELLULOSE  
O
OH
OR
OR
OO
RO
OR
OR
OR
O
R
R = H,  CH3 or H2C O
CH3
H
X
n
 
It is mixed alkyl hydroxyl cellulose ether and may be regarded as the propylene glycol 
of methyl cellulose .   
Non-proprietary Name: 
USP    :  Hydroxylpropyl methyl cellulose 2208, 2906, 2910. 
BPC             : Hypromellose 
Serviceable Categories: 
     
                          USP:Suspending and viscosity-increasing agent, tablet binder  coating agent. 
                          BP :Viscosity increasing agent; adhesive anhydrous ointment ingredient. 
         Other        : Film former, emulsion stabilizer. 
         Chemical name : Cellulose - 2-hydroxy propyl methyl ether. 
         Empirical formula :C8H15O6-(C10H18O)n- C8H15O5. 
        Grades: Methocel - E5, E15, E4M, R50, F4M, K100, K4M, K15M, K100M. 
          Descrription  : An odorless, tasteless, white or creamy white fibrous or granular 
powder. 
         Molecular weight :  Approximately 80,000. 
         Density               :  0.25 – 0.70g/cm3 
         Viscosity               :  HPMC-E15, 15 cps (2% aqueous solution),  
      HPMC-E4M, 4000 cps (2% aqueous solution) 
    HPMC-K4M, 4000 cps (2% aqueous solution) 
          PH                       :  6.0 – 8.0 (1% aqueous solution) 
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Typical Properties: 
Specific gravity       :  Approximately 1.3 
Apparent density   :  0.25 – 0.70g/cm3 
Browning temperature :  190 – 2000C (374-3920F) 
            Charring temperature : 225 – 2300C (437 – 4460F) 
             Enzyme resistance  :  Comparatively enzyme-resistance providing  excellent 
viscosity stability during long term storage. 
                            
 Solubility: 
                  Soluble in cold water, forming a viscous colloidal   solution. Insoluble in ether, 
alcohol and chloroform. But   soluble in mixtures of methanol and methylene chloride. 
Certain grades are soluble in aqueous acetone, mixtures of methylene chloride and isopropyl 
alcohol and other organic solvents. 
 
Stability: Very stable in dry conditions 
Safety: Hydroxy propyl methylcellulose has been shown to be safe in humans and in 
animals. 
 
Incompatibility:It is in compatible at extreme pH conditions and in the presence of oxidizing 
materials 
Applications in pharmaceutical formulations 
 It is used as a film former, lower viscosity grades are used in aqueous film coating 
and higher viscosity grades are used in solvent film coating.[37]  The concentration varies 
from 2 to 10% depending upon viscosity grade of the polymer.  It is also used as tablet 
binder. The E grades are generally suitable as film former while the K grades are used as 
thickeners.  
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6.2  SODIUM ALGINATE [38] 
Nonproprietary Names 
     BP  :Sodium Alginate 
     PhEur :Sodium Alginate 
     USP-NF :Sodium Alginate 
Synonyms 
       Alginato sodico; algin; alginic acid, sodium salt;   E401; Kelcosol;Keltone; natrii alginas; 
Protanal;   sodium polymannuronate. 
Chemical Name and CAS Registry Number: 
       Sodium alginate [9005-38-3] 
Empirical Formula : 
       Sodium alginate consists chiefly of the sodium salt of  alginic acid,which is    a mixture 
of polyuronic acids composed of residues of Dmannuronic acid  and L-guluronic acid. 
Functional Category: 
      Stabilizing agent;  
      Suspending agent;  
      Tablet and capsule disintegrant; 
      Tablet binder; 
      Viscosity increasing agent.of sodium chloride is present. 
Applications in Pharmaceutical Formulation :[39,40] 
1   Sodium alginate is used in a variety of oral and topical pharmaceutical     
formulations. 
2   In tablet formulations, sodium alginate may be used as both a binder and 
disintegrant; 
3   It has been used as a diluent in capsule formulations 
4 Sodium alginate has also been used in the preparation of sustained-release oral 
formulations since it can delay the dissolution of a drug from tablets, 
5 Aqueous suspensions. 
6 The effects of particle size, viscosity and chemical composition of sodium alginate 
on drug release from matrix tablets have been described. 
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Description 
         Sodium alginate occurs as an odorless and tasteless, white to pale yellowish-brown 
colored powder. 
 
Uses of sodium alginate. 
Pastes and creams              5–10 
Stabilizer in emulsions      1–3 
Suspending agent              1–5 
Tablet binder                     1–3 
Tablet disintegrant            2.5–10 
 
Pharmacopeial Specifications 
Microbial limits - 41000 cfu/g 4200 cfu/g 
Loss on drying - 415.0% 415.0% 
Ash    - 18.0–27.0% 
Sulfated ash  - 30.0–36.0%  
Arsenic   - 41.5 ppm 
Calcium   -41.5%  
Chlorides  -41.0% 
Lead    - 40.001% 
Heavy metals  -420 ppm 40.004% 
Assay (dried basis) -90.8–106.0% 
 
 
Stability and Storage Conditions 
Sodium alginate is a hygroscopic material, although it is stable if stored at low 
relative humidifies and a cool temperature. Aqueous solutions of sodium alginate are most 
stable at pH4–10. Below pH 3, alginic acid is precipitated. A 1% w/v aqueous solution of 
sodium alginate exposed to differing temperatures had a viscosity 60–80% of its original 
value after storage for 2 years.(39)Solutions should not be stored in metal containers. Sodium 
alginate solutions are susceptible on storage to microbial spoilage, which may affect solution 
viscosity. Solutions are ideally 
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Incompatibilities 
Sodium alginate is incompatible with acridness derivatives, crystal violet, phenyl 
mercuric acetate and nitrate, calcium salts, heavy metals, and ethanol in concentrations 
greater than 5%. Low concentrations of electrolytes cause an increase in viscosity but high 
electrolyte concentrations cause salting-out of sodium alginate; salting-out occurs if more 
than 4%. 
 
6.3. AVICEL PH101: [41] 
  Synonyms  
       Micro crystalline cellulose. 
Alternate product name: 
        Avicel PH 102,103,105,112,113,200,301,302,200LM. 
Physical and Chemical properties:  
       Odour- ordourless 
       Appearance- white, free flowing powder 
       PH – (In solution) 5.0-7.0 (11% solid dispersion) 
       Specific gravity- (H20=1) Bulk density,0.2-0.5/cc 
Incompatibilities: 
      Incompatible with strong oxidizing agents 
 Applications: 
      -Roller compaction 
      -Wet granulation 
      - Direct compression 
       -Extrusion/spheroiozation   
          
 
6.4. MAGNESIUM STEARATE:[42] 
Synonyms:  
      Dibasic magnesium stearate; Magnesium distearate; Magnesium octadexonate; Octa 
deconic acid; Magnesium salt; stearic acid 
Empirical Formula:  
     C3H6O7MgO4  
Functional Category: 
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     Tablet and capsule as lubricant. 
Description: 
     Magnesium stearate is a very fine powder, white precipitated milled, having a faint odour 
of stearic acid. 
Solubility: 
      Insoluble in ethanol, ethanol (95%), ether& water; slightly soluble in warm benzene & 
warm ethanol. 
Stability & storage: 
      Magnesium stearate is stable; it is closed in a container stored in cool dry place.   
Incompatibilities: 
      Incompatible with strong acids, alkali and iron salts. Avoid mixing with strong oxidized 
materials. Magnesium stearate cannot be used in products containing aspirin, some vitamins 
& most alkaloid salts. 
Applications: 
      Magnesium stearate is widely used in cosmetics, food& and pharmaceutical formulations. 
It is primary used as lubricant in capsule and tablet manufacturing at concentrations between 
0.25% and 5.0% w/w .It is also used in barrier cream.       
 
2.6. TALC:[43] 
Synonyms: 
       Kerolite 
       Magnesium talc      
       Soap stone 
       Steatite-Massive 
Chemical formula: 
        Mg3 Si 4O 10(0H) 2 
 Molecular weight: 
        379.27 
Density: 
       2.7-2.8 
Solubility: 
       Not soluble in water, slightly soluble in dilute mineral acids 
Stability: 
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       Stable 
Storage: 
       Stored in air tight container 
Applications: 
       Talc widely used in oral dosage formulation as a lubricant and diluents. It is widely used 
as dissolution retardant in the development of controlled release products. Talc is also used as 
a lubricant in tablet formulations, in a novel powder coating for extended release pellets and 
as an adsorbent. 
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7. MATERIALS AND EQUIPMENTS: 
7.1 MATERIALS: 
 
S.N0 MATERAILS COMPANY 
1 Venlafaxine hydrochloride Celon laboratories,   Hyderabad. 
2 Hpmc K15M Sigma chemical limited, Bangalore. 
3 Sodium alginate SD fine chemical limited, Mumbai. 
4 Avicel PH101 Sigma chemical limited, Bangalore. 
5 Magnesium stearate SD fine chemical limited, Mumbai. 
6 Talc SD fine chemical limited, Mumbai. 
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7.2 EQUIPMENTS: 
S.NO EQUIPMENT MANUFACTURE MODEL NO 
1 Electronic semi micro 
balance 
Sartorius ME 2350 
2 Mesh Retsec - 
3 Tapped density tester Electro lab ETD-2 
4 Electromagnetic sieve shaker Electro pharma EMS-8 
5 Rapid mixer granulator Diosna ESS355-002 
6 Retch drier Retch TG200 
7 Compression machine(single 
rotatory) 
Cad match CMD3-16 
8 Dissolution test apparatus Electro lab ED-22 
9 Hardness tester Dr Scheleuniger 
pharmatron 
8M 
10 Moisture balance Sartorius MA-I50 
11 Friabilator Electro lab EF-100 
12 Induction sealer Sigma jr electronic 
devices 
Csp-200 
13 Stability chambers Thermo lab - 
14 IR Spectrophotometer Perkin Elmer 1600 
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8. EXPERIMENTAL SECTION: 
8.1 PREFORMULATION STUDIES: 
               Preformulation testing is an investigation of physical and chemical properties of 
drug substance alone and when combined with excipients. It is the first step in the rational 
development of dosage forms. 
                                            The overall objective of preformulation testing is to generate 
information useful to the formulator in developing stable and bio-available dosage forms. The 
scope of Preformulation parameters maximizes the changes in formulating an acceptable, 
safe, efficacious and stable product. 
                                          In the present study, therefore, calibration of Venlafaxine 
hydrochloride, compatibility with the selected polymers using FTIR peak matching, etc 
 
8.2. DEVELOPMENT OF CALIBRATION CURVE FOR VENLAFAXINE 
HYDROCHLORIDE: 
 As have Venlafaxine hydrochloride high solubility, so the calibration curve 
was obtained by using distilled water. 
 A stock solution of Venlafaxine hydrochloride was prepared by dissolving 
100 mg of the drug in 100 ml of distilled water to get 1 mg/ml solution(stock solution). From 
this 10 ml of solution was pipette out and diluted to 100 ml using distilled water to produce 
100 µg/ ml, from this 0.5ml of solution was diluted to 10 ml using water to get 5 µg/ ml. from 
this working stock solution, dilution were made with distilled water to produce 10, 15, 20, 
and 25 µg/ ml. The λmax of the drug was determined by scanning one of the middle 
concentration between 200 nm to 400nm using a cyber lab uv 100 double spectrophotometer. 
At this wavelength, the absorbance’s of all the dilutions were measured against the blank. 
Standard curve between concentration and absorbance was plotted and slope (K) and 
intercept (B) values were determine. 
 
7.3 COMPATIBILITY STUDIES:  
                                                     Infrared spectra matching approach was used for the 
detection of any possible chemical reaction between the drug and the polymer.  A physical 
mixture (1:1) of drug and polymer was prepared and mixed with suitable quantity of 
potassium bromide.  About 100mg of this mixture was compressed to form a transparent 
pellet using a hydraulic press at 10 tons pressure. It was scanned from 4000 to 400 cm-1 in a 
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Shimadzu FTIR spectrophotometer. The IR spectrum of the physical mixture was compared 
with those of pure drug and polymers and matching was done to detect any appearance or 
disappearance of peak. 
 
8.4 FORMULATION DEVELOPMENT: 
                                                   Matrix tablets of Venlafaxine hydrochloride were formulated 
by using HPMC K15M and sodium alginate as a polymers and were prepared by wet 
granulation technique.  
                                                    In the formulation of matrix  tablets, Venlafaxine 
hydrochloride was used as model drug, selected HPMC K15M and sodium alginate were 
used as polymer, Microcrystalline cellulose (Avicel pH 101) was used as diluents, Talc and 
Magnesium stearate used as lubricant and glidant. 
 
8.5 PREPARATION OF GRANULES AND COMPRESSION OF TABLETS :[44] 
                             The granules were prepared by wet granulation technique and water was 
used as granulating agent. Accurately weighed quantities of the ingredients were pass through 
sieve no 16 and mixed with planetary mixer required quantity of water was added and mixed 
thoroughly until get suitable granules. The granules were passing through British Standard 
Sieve (BSS) No.16. Wet granules were dried in hot air oven for at 60oc till to get the 
moisture content approximately 3% and again passed through BBS No. 22 mesh granules 
were placed on the rotating hydraulic 8 station compression machine and compressed into 
tablets of 200mg each tablet with the following qualities  
                 1. Tablet weight 
                 2. Diameter 
                 3. Thickness 
                 4. Hardness 
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8.6 THE GENERAL FORMULA IS GIVEN IN THE BELOW TABLE: 
TABLE NO: 3 General formula     
 
                   
S.No. Name of the ingredient Quantity per tablet (mg) Uses 
1 Venlafaxine 
hydrochloride 
100mg Drug 
2 Hpmc k15M 25 to75mg Polymer 
3 Sodium alginate 2 to 3mg Polymer 
4 Avicel pH 101 18 to 70mg Diluents 
 
6 Magnesium stearate  
 
2mg Lubricant 
 
7 Talc 2mg Glidant 
     8                Water                     q.s         Granulating agent        
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8.7 FORMULATION OF DIFFERENT BATCHES IS GIVEN IN THE                        
TABLET: 
Table no: 4 Formulation for different batches 
       
      
INGREDIENTS 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Venlafaxine 
hydrochloride 
100 100 100 100 100 100 100 100 100 
Hpmc k15M 25 75 50 75 75 45 25 40 25 
Sodium alginate 2 3 3 2 2.5 2.5 2 2.5 3 
Avicel pH 101 68.5 18 43 19 18.5 43.5 69 44 68 
Magnesium 
stearate 
2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 
Water q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Total 200 200 200 200 200 200 200 200 200 
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8.8 PRECOMPRESSION EVALUATION OF GRANULES: 
 
8.8.1 Angle of Repose:     
                          The angle of repose of the prepared pellets was measured by funnel method. 
A dry clean funnel was kept on a burette stand at particular height (2-3cm). A graph paper 
was placed on the flat surface and a sufficient quantity of the spheroids was allowed to flow 
slowly through the funnel until the heap touched the tip of the funnel. The circumference of 
the heap was drawn and the midpoint was located and its radius was measured. The angle of 
repose was calculated by: 
                                     Tan θ = h/r or θ =tan-1h/r. 
    Where,     h = height of pile; 
                    r = radius of the base of the pile and  
                    θ = angle of repose.  
 
8.8.2 Bulk density: 
                    The bulk density of the prepared granules was measured by automated tape. A 
weighed amount of granules was introduced into a graduated measuring cylinder. The 
cylinder was fixed on the bulk density apparatus and the timer knob was set for hundred 
tapping. After tapping the volume occupied by the granules was noted as final volume. Then 
the bulk density was calculated using: 
                        Bulk density =   Wt. of sample (g) / Final volume (cc) 
 
8.8.3 Measures of Powder Compressibility: 
                                                          The Carr’s Index and Hausner Ratio are measures of the 
propensity of a powder to be compressed. As such, they are measures of the relative 
importance of inter particulate interactions. As such, they are measures of the relative 
importance of inter particulate interactions. In a free-flowing powder, such interactions are 
generally less significant, and the bulk and tapped densities will be closer in value. For poorer 
flowing materials, there are frequently greater inter particle interactions and a greater 
difference between the bulk and tapped densities will be observed. These differences are 
reflected in the Carr’s Index and the Hausner Ratio, which are calculated using the following 
formula:                  
                                   Carr’s Index =   (Vr-Vo) X 100 / Vr 
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Where, 
                                 Vr = Tapped density  
                                  Vo = Bulk density 
8.8.4 True density: 
                    The true density of the prepared granules was determined by liquid displacement 
method.  
Select a solvent in which the granules are insoluble and heavy.  
Method: Pycnometer or specific gravity bottles may be used. 
Weight of Pycnometer = W1 
Weight of Pycnometer + sample = W2 
Weight of sample = W3 = W2 - W1 
Weight of Pycnometer with sample and filled with solvent = W4 
Weight of liquid displaced by solid = W4 - W2 
 
         True Density = W2 - W1 
                             W4 - W2 
8.8.5 Porosity:   
             Porosity is defined as the ratio of void volume to the bulk volume. It is calculated by 
using the formula: 
 
       Porosity = 1 - Bulk Density 
                            True Density    
 
8.8.6 Hausner Ratio: 
It is the ratio of taped density to bulk density  
Vo/ Vf 
                   Where, 
                              Vo = Bulk volume; 
                              Vf = Tapped volume. 
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8.9 POST COMPRESSION EVALUATION OF THE TABLET: 
  The prepared tablets were subjected for various quality control tests in 
order to characterize them. 
 
8.9.1 Weight Variation:                                        
  The weight variation test of the tablets was done as per the guidelines of 
Indian Pharmacopoeia.   Ten tablets from each batch were weighed in digital balance and 
average weight was determined and standard deviation was calculated. 
Weight Variation limits as per USP: 
  Average weight in mg.  % ± deviation allowed 
  130 or less       10 
                                    130-223                                         7.5 
                                    More than 324         5                                                    
 
 
8.9.2 Friability:    
                Friability is the measure of a tablet’s ability to with stands both shock and abrasion 
without crumbling during the handling of manufacturing, packing, shipping and consumer 
use.  The weight of 10 tablets was noted and placed them in Roche friabilator.  The device 
subjects the tablets to the combined effect of shock and abrasion by utilizing a plastic 
chamber, which revolves at 25 rpm, dropping the tablets a distance of 6 inches with the 
revolution.  The pre-weighed tablet sample is removed after 100 revolutions, dusted and 
reweighed. Tablets that loose less than 0.5 to 1 percent in weight are generally considered 
acceptable. 
                     
 
                                 Initial wt. of 10 tablets-final wt. of 10 tablets 
Friability (%) = -------------------------------------------------------------------------- * 100 
                                 Initial wt of 10 tablets 
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8.9.3 Hardness:  
               Hardness of the tablet is an indication of its strength. It is tested by measuring the 
force required to break the tablet across the diameter. The force is measured in kg/cm2 and 
the hardness of about 4 kg/cm2 is considered to be satisfactory for uncoated tablets. Tablet  
requires a certain amount of mechanical strength to withstand the shock of handling during its 
manufacture, packaging, shipping and dispensing. It may be especially important to monitor 
the tablet hardness for sustained release drug products or other products that possess real or 
potential bioavailability problems are sensitive to variations in drug release profile.  The 
crushing strength that just causes the tablet to break is recorded by means of Monsanto 
hardness tester.  
  
 
8.9.4 Swelling index: [51] 
                  The swelling and erosion studies were performed according to the method 
reported by Al-Taani and Tashtoush, to understand the influence of swelling and erosion 
behaviour on drug release. Matrix tablets were introduced into the dissolution apparatus 
under the standard set of condition as specified for drug release rate studies. The tablets were 
removed using small basket and the swollen weight of each tablet was determined. To 
determine the matrix erosion, swollen tablets were dried in a vacuum oven at 450C to a 
constant weight. 
Calculations:  
 
                     Swelling Index = (Mt-Mo)/Mo X 100 
                    Where Mt – weight of tablet at time ‘t’ 
                    Mo – weight of tablet at time t=o 
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8.9.5 Drug content: 
                               Accurately weigh 20 tablets and crushed in a motor; a quantity of powder 
equivalent to label claim Venlafaxine hydrochloride disperse in methanol, shake and dilute to 
100ml with methanol and filter. Dilute 20ml of filtrate to 100ml with methanol. Measure the 
absorbance resulting solution at maximum at about 225nm by using UV-Visible 
spectroscopy. 
Calculations: 
                             Drug content         
                          %Drug content = ------------------- *100 
                                                          Label claim 
 
 
8.10 DISSOLUTION TEST: [45] 
                                          Dissolution studies were performed using USP (II) standard 
dissolution apparatus at 37 ± 0.5ºC. The Tablet was placed in 900ml of dissolution medium 
and rotated at 50 rpm. The dissolution Media used was distilled water.  
                                                During the test 10 ml of the sample was withdrawn at specific 
time intervals 30,60,90,120,150,180,240,360 and 480min after each withdrawal, same 
volume of fresh dissolution medium was added to maintain sink condition. 
DISSOLUTION CONDITIONS:  
Table no: 5 Dissolution parameters 
 
 
 
 
 
S.No Parameters Specifications 
1. Apparatus USP(II) 
2. Medium water 
3. Volume 900ml 
4. Rpm 50 
5. Temperature 37±0.5°C 
6. Time interval 
30,60,90,120,150,180,240,360 and 
480min 
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8.11. Proposed mathematical models to explain the nature and mechanism of drug    
release from matrix tablets:[46,47,48] 
8.11.1 Zero –order release model: 
                 The zero order rate equation describes the systems, where the drug release 
rate independent of its concentration. The time verses % cumulative drug release graph 
was plotted.            
                                               Qt=kot 
8.11.2 First-order release model: 
                The first order rate equation describes the release from the systems,where 
release rate is concentration dependent. The time versus log of cumulative drug release 
graph was plotted. 
                                           InQ=InQot 
8.11.3 Higuchi square root model: 
                  The equation describes the release of drug from insoluble matrix as square 
root of time dependent process based on Fickian diffusion .The square root of tme 
versus % cumulative drug release is plotted 
                                          Qt=t1/2 
8.11.4 Korsmeyer- Peppas Model: 
             The model which represents a better fit for the formulations. According to this 
methods log of average percentage cumulative drug release versus log of time curve was 
plotted .From the slope value of exponent ‘n’ was calculated, and the value could be used to 
characterize different release mechanisms as 
                                 Mt/Ma=Ktn  
 
Table no: 6 Interpretations of Diffusion Mechanisms from Dosage Form 
 
Release exponent 
(n) 
Drug transport 
mechanism 
Rate as a function of 
time 
0.5 Fickian diffusion t-0.5 
0.5<n<1.0 Anomalous transport tn-1 
1.0 Case-II transport Zero order release 
Higher than 1.0 Super case-II transport tn-1 
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Where, 
           Qt =Amount of drug release in time t’ 
           Qo =Initial amount of drug in tablet 
           S =Surface area oh tablet 
           KO,K1,KH=Release rate constant of Zero order, First order, Higuchi rate equation. 
           Mt/Ma=fraction drug release in to dissolution medium  
 
7.12 STABILITY STUDIES:[49] 
                                          Stability of a formulation can be defined as the time from date on 
manufacture of the formulation until its chemical or biological activity is not less than a 
predetermined level of labelled potency and its physical characteristics have not changed 
appreciably or deleteriously. 
                                         Formulation and the development of a pharmaceutical product are 
not complete without proper stability analysis, carried out on it to assess the physical and 
chemical stability and the safety. . The purpose of stability testing is to provide evidence on 
 
 
 
how the quality of a drug substance or drug product varies with time. Under the influence of a 
variety of environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf lives. 
                                         Generally, the observation of the rate at which the product degrades 
under normal room temperature requires a long time. To avoid the undesirable delay, the 
principles of accelerated stability studies are adopted. 
                                         The different temperature and humidity condition, prescribed by the 
International Conference on Harmonization (ICH) for zone IV were employed namely  [50] 
                       1. 250C with 60% Relative humidity (RH)  
                       2.  400C with 75% Relative humidity (RH) 
                      3. Room temperature. 
            The ideal batches of the formulated matrix tablets containing 100 mg venlafaxine 
were packed in polyethylene bags and then kept in stability chamber at 25°C/60% RH, 
400C/75% RH and room temperature. Samples were withdrawn at 15, 30 and 60 days and 
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evaluated for their physical appearance, drug content and in vitro drug release at specified 
intervals of time. T80 was also calculated by using dissolution studies. (Kulkarni G.T., 2004) 
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9. RESULTS AND DISSCUSION: 
 9.1 RESULTS: 
 9.1.1 PREFORMULATION STUDIES: 
 
 
 9.1.1 Development of calibration curve for Venlafaxine hydrochloride 
       
     Table no: 7 Standard curve for Venlafaxine hydrochloride.                            
 
    
 
 
 
 
 
 
 
 
 
 
 
Con of solution Absorbance at 225 nm Conμg/ml 
5 0.203 0.203 
10 0.370 0370 
15 0.539 0.539 
20 0.741 0.741 
25 0.904 0.904 
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Standard curve graph for Venlafaxine hydrochloride 
 
 
 
Figure no:5 calibration curve for Venlafaxine hydro chloride 
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9.2: Compatibility studies: 
9.2.1: Table No: 8 Drug and Exicipient Compatibility study: 
Sr. 
No Name of the Excipient 
API: 
Excipient 
Initial 
Observati
on 
Final 
observation 
 
conclusion    40°C/75% RH 
2nd 
week 
4th 
week 
1 API (venlaflaxin hydro chloride) --- 
White 
crystalline 
powder 
White 
crystall
ine 
powder
White 
crystalli
ne 
powder 
Compatible 
2 API+ HPMC K15M  1 :1 White fine powder 
White 
fine 
powder
White 
fine 
powder 
Compatible 
3 API   + sodium alginate 1 : 1  
White fine 
powder 
White 
fine 
powder
White 
fine 
powder 
Compatible 
4 API  +  Avicel PH101 1 : 1  
White fine 
powder 
White 
fine 
powder
White 
fine 
powder 
Compatible 
6 API   +  Mg. Stearate 1 : 0.05  
White 
powder 
White 
powder
 White 
Powder Compatible 
7 API +Talc 1:0.05 White powder 
White 
powder
White 
powder Compatible 
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9.2.2: Sample no. 1: Venlafaxine hydrochloride 
 
Figure no: 6 Venlafaxine hydrochloride.  
 9.2.3: Sample no.2:  HPMC K15 M   : 
   
 
 
Figure no:7 HPMC K15 M 
 
 
 
                                                         RESULTS AND DISSCUSSION 
 
Page 61 
 
9.2.4:  Sample no. 3: sodium alginate:  
  
 
 
Figure no:8 Sodium alginate 
 
9.2.5: Sample no. 4: Venlafaxine hydrochloride +HPMCK15M +sodium alginate  
 
Figure no :9 Venlafaxine hydrochloride+HPMC+Sodium aliginate 
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TABLE NO:9 INTERPRETATION OF VENLAFAXINE HYDROCHLORIDE, 
HPMCK15M AND GRANULES CONTAINING WATER AS GRANULATING AGENT: 
PEAKS Cm-1 GROUPS STRECHING/DEFORMATION
3320 O-H Streching 
1208 C-O Streching 
2875 Aliphatic C-H Stretching 
1245 Asymmetric C-O-C Streching 
1039 Symmetric C-O-C Streching 
 
 
9.3 PRECOMPRESSION RESULTS FOR EVALUATION OF VENLAFAXINE 
HYDROCHLORIDE GRANULES: 
TABLE NO: 10  
                    The prepared granules were subjected for various evaluation tests in order to 
characterize them. 
 
FORMULAIONS         F1          F2          F3           F4 
Angle of repose 19.73 
±0.453 
18.24 
±0.234 
17.23 
±0.211 
17.92 
±0.116 
Bulk density 
Tapped 
 
Untapped 
0.463 
±0.012 
0.334 
±0.006 
0.481 
±0.010 
0.404 
±0.010 
0.474 
±0.013 
0.401 
±0.009 
0.488 
±0.025 
0.388 
±0.025 
True density 16.969 
±1.031 
16.20 
±0.905 
14.26 
±0.923 
21.0 
±1.218 
Compressibility 0.638 
±0.047 
0.617 
±0.032 
0.621 
±0.029 
0.631 
±0.010 
% Porosity 27.087 
±1.731 
21.989 
±1.062 
13.928 
±1.801 
22.55 
±1.711 
Hausner ‘s ratio 1.204 
±0.015 
1.190 
±0.014 
1.195 
±0.022 
1.259 
±0.015 
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FORMULAIONS F5 F6 F7 F8 F9 
Angle of repose 
 
19.53 
±0.321 
16.52 
±0.243 
21.20 
±0.437 
16.72 
±0.231 
20.54 
±0.452 
 Bulk density 
Tapped 
 
Untapped  
0.509 
±0.006 
0.378 
±0.010 
0.463 
±0.012 
0.334 
±0.006 
0.486 
±0.022 
0.398 
±0.011 
0.468 
±0.014 
0.402 
±0.004 
0.505 
±0.010 
0.362 
±0.052 
True density 23.71 
±0.272 
16.96 
±1.031 
18.10 
±1.401 
13.87 
±1.883 
23.108 
±1.112 
 Compressibility  0.624 
±0.050 
0.609 
±0.030 
0.608 
±0.054 
0.631 
±0.009 
0.624 
±0.005 
% Porosity 18.117 
±1.615 
23.792 
±1.714 
19.614 
±1.900 
20.956 
±1.510 
19.079 
±1.419 
Hausner ‘s ratio 1.291 
±0.019 
1.204 
±0.015 
1.221 
±0.020 
1.161 
±0.015 
1.419 
±0.225 
 
 
Table no: 9.3.1 evaluation of granules 
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9.4 POST COMPRESSION EVALUATION TESTS FOR PREPARED TABLETS: 
 Table no: 11 Evaluation of tablets for F1,F2,F3,F4, 
FORMULATIONS F1 F2 F3 F4 
Weight variation  202.8 
±2.500 
200.7 
±1.756 
198.96 
±0.954 
200.20 
±1.935 
Friability 0.010 
±0.005 
0.053 
±0.002 
0.006 
±0.003 
0.019 
±0.005 
 
Hardness 4.700 
±0.208 
4.100 
±0.100 
4.333 
±0.152 
3.700 
±0.200 
Drug content 99.2 
±0.166 
92.55 
±0.156 
95.23 
±0.174 
96.6 
±0.242 
Swelling index 2.12 
±0.30 
2.13 
±0.90 
2.07 
0±.043 
2.04 
±0.223 
 
Table no: 11 Evaluation of tablets for F5, F6, F7, F8,F9. 
FORMULATIONS F5 F6 F7 F8 F9 
Weight variation 197.13 
±1.577 
198.4 
±0.374 
203.1 
±2.128 
200.26 
±0.251 
205.76 
±2.134 
Friability 0.034 
±0.003 
0.033 
±0.003 
0.032 
±0.019 
0.036 
±0.064 
0.038 
±0.031 
Hardness 4.0 
±0.200 
4.100 
±0.100 
4.500 
±0.351 
4.233 
±0.251 
5.00 
±0.100 
Drug content 97.7 
±0.180 
93.55 
±0.239 
98.44 
±0.234 
93.55 
±0.241 
98.3 
±0.650 
Swelling index 2.15 
±0.305 
2.010 
±0.356 
2.045 
±0.224 
2.05 
±0.010 
2.05 
±0.043 
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9.5 DISSOLUTION STUDIES:  
TABLE NO: 12 DISSOLUTION STUDIES. 
S.No          Parameters Specifications 
         1. Apparatus USP(II) 
         2. Medium Distilled water 
         3. Volume 900ml 
         4. Rpm 50 
         5. Temperature 37±0.5°C 
         6.  Time interval 30,60,90,120,150,180,240,360min  
 
 
 9.5.1 IN VITRO DISSOLUTION PROFILE OF FORMULATIONS: 
Table no: 13 Release profile for formulations. 
TIME 
(hrs) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 33.58 18.51 19.02 15.59 21.21 18.84 22.31 19.71 10.11 
2 44.06 21.99 27.38 21.21 23.85 29.96 34.62 25.02 16.63 
3 47.82 24.22 33.57 25.91 27.42 40.47 38.58 37.67 20.56 
4 50.12 25.20 38.15 28.38 36.09 44.28 41.64 41.71 25.44 
5 51.10 25.90 41.03 31.06 27.96 48.32 43.41 53.22 28.24 
6 50.72 26.15 46.29 31.25 28.14 52.55 45.03 59.22 33.80 
7 38.72 26.39 49.82 32.06 27.36 58.74 47.25 62.10 35.33 
8 36.34 26.16 52.23 31.85 24.66 60.82 45.99 68.28 37.80 
9 32.56 26.20 56.18 32.13 23.77 65.47 37.23 72.41 41.31 
10 28.78 27.83 62.01 31.03 20.89 69.81 39.22 77.53 36.89 
11 26.02 27.99 67.41 24.75 17.54 76.50 40.28 82.64 37.67 
12 23.57 30.33 74.45 23.01 13.35 80.11 42.12 87.54 38.78 
13 14.34 33.57 81.39 20.45 12.08 84.32 43.34 94.32 45.46 
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9.5.2 DRUG RELEASE PROFILE GRAPH FOR FORMULATINS F3,F6,F8: 
 
 
Figure no: 10 Invitro Drug release profile graph for Formulations F3, F6, F8. 
. 
  
 
9 .5.3: t80% DATA FOR FORMULATIONS F3, F6, F8: 
Table no: 14  t80%  data for formulations F3, F6, F8. 
    
FORMULATION 
CODE 
F3 F6 F8 
TIME AT 80% OF 
DRUG RELEASED 
12.80 hrs 11.70hrs 10.50hrs 
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9.6 KINETIC MODELS FOR DRUG RELEASED: 
Table no: 15 kinetics model for F8: 
TIME 
(Hrs) 
Cu % 
DRUG 
RELEASE 
% DRUG 
REMAINING 
SQRT 
TIME 
Log Cu % 
DRUG 
REMAINING 
Log 
TIME 
Log Cu % 
DRUG 
RELEASE 
0 0.00 100 0.00 2.00 0.00 0.00 
1 19.71 80.29 1.00 1.90 0.00 1.29 
2 25.02 74.98 1.41 1.87 0.30 1.39 
3 37.67 62.33 1.73 1.79 0.47 1.57 
4 41.71 58.29 2.00 1.76 0.60 1.62 
5 53.22 46.78 2.23 1.67 0.69 1.72 
6 59.22 40.78 2.44 1.61 0.77 1.77 
7 62.10 37.90 2.64 1.57 0.84 1.79 
8 68.28 31.72 2.82 1.50 0.90 1.83 
9 72.41 27.59 3.00 1.43 0.95 1.85 
10 77.53 22.47 3.16 1.35 1.00 1.88 
11 82.64 17.36 3.31 1.23 1.04 1.91 
12 87.54 12.26 3.46 1.09 1.07 1.94 
13 94.32 4.49 3.60 0.65 1.11 1.98 
 
 
 
9.7 RELEASE MODELS GRAPH FOR OPTIMIZED FORMULA: 
9.7.1 ZERO ORDER RELEASE MODELFOR F8: 
 
 
Figure no :11 Zero order release model graph for F8 
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9.7.2 FIRST ORDER RELEASE MODEL FOR F8:  
  
Figure no : 12 First order release model graph for F8 
 
9.7.3. HIGUCHI MATRIX MODEL FOR F8: 
 
 
 
Figure no: 13 Higuchi model graph for F8.  
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9.7.4. KROSMEYER PEPPAS   RELEASE MODEL FOR F3 
 
  
 
Figure no: 14 Krosmeyer order model graph for F8. 
 
 
 
 
TABLE NO: 16 R and N values from the above data 
 
 
 
 
 
Best fitting model is Peppas model 
 
FOMULATION 
CODE 
Zero 
order 
1st 
order  
Higuchi 
matrix 
Peppas N 
values 
F8 batch _ 0.6877 0.9245 0.9949 0.3017
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9.8 STABILITY STUDIES: 
Table no:17 Stability study for F8. 
s.no  Evaluation parameters F8 batch 
15 days                30 days                 60 days 
1 Physical Appearance No significant 
change 
No significant 
change 
No significant 
change 
2 Average weight (mg) 198.94 
±0.954 
198.94 
±0.954 
198.94 
±0.954 
3 Hardness (kg/ cm2) 4.332 
±0.152 
 
4.332 
±0.152 
 
4.332 
±0.152 
 
4 Friability (%) 0.006 
±0.003 
 
0.006 
±0.003 
 
0.006 
±0.003 
 
5 Swelling index 2.07 
±0.043 
 
2.07 
±0.043 
 
 2.07 
±0.043 
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9.8.2 IN VITRO DISSOLUTION PROFILE OF VENLAFAXINE HYDROCHLORIDE 
MATRIX TABLET AFTER TWO MONTHS AT : 
 
 
Figure no:15 Invitro dissolution study 
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9.9 DISSCUCUSION: 
9.9.1 Development of calibration curve for Venlafaxine hydrochloride : 
The scanning of drug solution in UV range showed maximum absorbance at 225 nm and 
hence, the calibration curve was developed at this wavelength.  The calibration curve was 
linear between 5-25 µg/ml concentration range. The correlation coefficient ‘r’ was found to 
be 0.990. 
9.9.2 Compatibility studies: 
                  The compatibility between the drug and the selected excipients were evaluated 
using FTIR peak matching method.  The IR spectra of pure drug, polymers and the physical 
mixtures are shown in figures. There was no appearance or disappearance of peaks in the 
polymer –drug mixture, which confirmed the absence of any chemical interaction between 
the drug and the polymer.  
9.9.3 Discussion for design and formulation of matrix tablet: 
                     Venlafaxine hydrochloride sustained release matrix tablet was prepared by 
adding HPMC K15M as hydrophilic polymer, Sodium alginate as hydrophilic polymer, 
Avicel PH101 ,Magnesium stearate as lubricant and Talc as glidant.HPMCK15M is used retard 
the release drug from oral delivery system because of high viscosity. This extensive use 
originates from the non toxicity, high drug loading capacity and non PH dependent of the 
polymer. 
9.9.4 Evaluation of granules:  
                       Venlafaxine hydrochloride granules were characterized for angle of repose, 
bulk density, true density, % porosity, Hausner ratio and Compressibility. The results were 
satisfactory. The granules were lightish white in colour, odourless, amorphous in nature and 
slightly bitter in taste.  
9.9.5 Evaluation parameters for tablets: 
                   Venlafaxine hydrochloride tablets were characterized for Weight variation, 
hardness, friability, and drug content. The results were satisfactory. The swelling index  were 
statisfactory.The evaluated parameters were within acceptable range for all formulations. All 
the formulations pass the limit test. 
 
9.9.6 Invitro drug release profile: 
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The formulated 9 batches were conducted dissolution for 13 hours and the sample was 
analysed and found the drug release. Satisfactory release was got in F3, F6 and F8 batches 
shows 81.39, 84.32 and 94.32.For the above data t80 % is calculated .These shows release at 
10.50 hrs, 11.70 hrs and 12.80 hrs. As per t80% F8 can be taken as optimized formula, this 
batch undergoes kinetic model. Best fitting model is Peppas model therefore considered as 
optimized formulations. 
9.9.7 Stability studies:  
              Stability studies of F8 formulation Venlafaxine hydrochloride matrix tablet 
with HPMC K15 and sodium alginate were carried out at 25OC/60% RH. There is no 
significant change in release characteristics and physicochemical properties of the tablets 
used in the release study.  Based on the results it can be concluded that the formulated matrix 
tablets were stable at room temperature at different relative humidity over a period of 60 
days.   
                  F8 formulations were subjected to various evaluation parameters and the results 
obtained were within the range.  The weight variation test indicates that all the tablets were 
uniform weight.  Hardness of all the tablets were within the range of 4.23 Kg/cm2. 
 
9.9.8 Criteria for the selection of optimize formula: 
Venlafaxine hydrochloride is an anti depressant drug. It belongs to the category Bio 
pharmaceutics classification (BCS) 1.This is a high solubility and high permeability drug. 
Venlafaxine hydrochloride sustained release matrix tablet was prepared by adding HPMC 
K15M as hydrophilic polymer, Sodium alginate as hydrophilic polymer, Avicel PH101 
,Magnesium stearate as lubricant and Talc as glidant.HPMCK15M is used retard the release 
drug from oral delivery system because of high viscosity. As per cumulative percentage of 
drug release satisfactory release was got in F3, F6 and F8 batches  shows 81.39, 84.32 and 
94.32.For the above data t80 % is calculated .These shows release at 10.50 hrs,11,70 hrs and 
12.80 hrs .As per t80% data F8 shows as a ideal formulation, this batch undergoes kinetic 
model. Best fitting model is Peppas model to this drug release .The N value of F8 is0.33, it 
follows Fickain diffusion. 
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10.SUMMARY AND CONCLUSION: 
1. The aim was to develop a matrix formulation for oral delivery system for Venlafaxine 
hydrochloride using synthetic polymers to control release.  
2.  Based on the literature studies HPMC K15M and sodium alginate were choosen as a 
polymers for release rate control.  
3.The selected polymer was characterized for swelling index which are essential for design of 
suitable matrix  formulation In Preformulation studies, the compatibility between selected 
drug and polymer was tested by FTIR peak matching. 
4.In the formulation development, a matrix, tablet of Venlafaxine hydrochloride were 
prepared using HPMC K15M and sodium alginate  as a polymers and the effect of certain 
process and formulation variables such as  compressional force, compressional time and 
concentration of polymer on the physicochemical and in vitro drug release was studied.  
5.The kinetics of drug release was also determined by using Korsmeyer- Peppas equation. 
6.In aging study, the ideal batches of the formulated matrix tablets were kept in stability 
chamber at 25°C/60% RH. Samples were withdrawn at 15, 30 and 60 days and evaluated for 
their physical appearance, friability, hardness, weight variation, swelling index and in vitro 
dissolution study. 
 All the above investigations brought out many facts, which lead to the following conclusions 
 
10.The preformulation studies involving calibration curve development for the drug,  and 
compatibility between selected drug and polymer was found to be better  and incompatibility 
between drug and polymer shows that appears to be a better release rate control  polymers  
for matrix formulation. 
11.As per the time at which 80% drug released formulations F3,F6 and F8 was found to be 
10.50,11.70 and 12.80 hrs. 
12.The study on the various process formulation variables revealed that all the variables are 
important in developing a matrix tablet. A batch prepared with 40mg  Hpmc K15M and 2.5 
mg sodium alginate polymer concentration was identified as ideal batch based on its optimum 
hardness of 4.23kg/cm2 and percentage drug release was 94.32% F8 batch were found to be 
better. 
13.The formulation F8 having ‘n’ value 0.33 less than 0.5.Then this formulation follows 
Fickain diffusion according to these F8 formulations are optimized formulation. 
14.It is therefore expected to reduce  cost and ultimately improve the patient compliance. 
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